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ABSTRACT 
 
Depression, Treatment Response to TNFi, and Economic Outcomes among Working-Age 
Adults with Rheumatoid Arthritis 
Arijita Deb 
Depression is one of the most frequently occurring conditions in Rheumatoid Arthritis 
(RA) patients and understanding depression as a comorbidity in RA is very important. The link 
between RA and depression is very complex and influenced by a multitude of factors such as 
shared pathophysiologic pathways of inflammation, RA-related treatment response, as well as 
the patient’s demographic and socio-economic factors, and general difficulties in coping with the 
disease. Depression can increase the clinical, humanistic, and economic burden among RA 
patients. Growing evidence now suggests that depression is a systemic inflammatory condition 
and may exert a negative influence on the treatment response in RA by its effect on pro-
inflammatory cytokines. Therefore, it is important to understand how depression is related to the 
treatment effectiveness of specific cytokine inhibitor drugs such as Tumor Necrosis Factor 
Inhibitor (TNFi) therapy that are used for the treatment of RA.  The powerful anti-inflammatory 
effect of TNFi may have a potential beneficial effect in reducing the risk of depression in RA 
patients. It is important to gain a comprehensive understanding of how depression affects RA 
and how RA can affect depression in the real-world clinical practice settings, particularly among 
working-age individuals as the burden of depression is highest among working-age population. 
Therefore, this dissertation had three related aims focusing on working-age adults: 1) estimating 
the clinical, humanistic and economic burden of depression in RA; 2) examining the relationship 
between prevalent depression and treatment response to TNFi therapy in RA; and 3) evaluating 
the association between TNFi therapy and the risk of developing depression in RA.   The study 
used data from multiple nationally representative sources to triangulate the complex relationship 
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between RA and depression in working-age adults. These data sources were: the nationally 
representative Medical Expenditure Panel Survey (MEPS) for years 2009, 2011, 2013, and 2015 
and a retrospective claims database for commercially insured working-age adults for the years 
2009 through 2015. We found that one in every four working-age RA patients reported the 
presence of depression. RA patients with depression compared to RA patients without depression 
were significantly more likely to have pain-related interference with normal work, functional 
limitations, lower health-related quality of life (HRQoL) scores in the mental domain, higher 
annual healthcare expenditures and out-of-pocket spending burden, higher rate of 
unemployment, higher number of missed work days annually and higher lost annual wages due 
to missed work days. Depression was independently associated with treatment response to TNFi, 
even after adjusting for baseline predisposing, enabling, need and external environment factors 
among working-age RA patients. Among RA patients with depression, nearly three in every ten 
patients responded to TNFi therapy, whereas among RA patients without depression, nearly four 
in every ten patients responded to TNFi therapy. In addition, in a depression-free cohort of RA 
patients, those who responded to TNFi therapy were significantly less likely to develop newly-
diagnosed depression as compared to those who did not respond to TNFi therapy. In summary, 
these findings underscore the importance of effectively managing depression in routine clinical 
practice of RA patients to reduce pain, functional or activity limitations, improve quality of life, 
lower direct and indirect healthcare costs. In addition, the findings highlight the negative impact 
of depression on treatment response to TNFi and provide insights into specific subgroups of RA 
patients with depression who are at risk of responding poorly to TNFi. Furthermore, reduction in 
the risk of depression in TNFi responders suggests that TNFi therapy is important not only for 
clinical improvement in RA disease but also for reducing the risk of depression. 
 
 
iv 
 
Acknowledgement 
First and foremost, I would like to take this opportunity to thank Dr. Usha Sambamoorthi, 
my advisor and dissertation chair, whose relentless guidance, support and encouragement to 
pursue my research interests were instrumental for the completion of this dissertation. It was a 
great privilege to have her as my advisor and I have been immensely benefitted by taking the 
courses that she has offered and by working with her on several projects. Her constant oversight, 
thoughtful advice, and prompt feedback were absolutely invaluable. I would also like to express 
my sincere gratitude to my committee members Dr. Nilanjana Dwibedi, Dr. Wenhui Wei, Dr. 
Traci LeMasters and Dr. JoAnn Hornsby for their scientific contributions, ideas, and valuable 
suggestions. Special thanks to Dr. Nilanjana Dwibedi, Dr. Suresh Madhavan and Dr. Xi Tan in 
helping me with the data acquisition. I would also like to sincerely acknowledge and thank all 
the faculty and graduate students of the PSP department for their guidance and support. Last but 
not the least, I am extremely thankful to my parents and Sumit for their unconditional love, 
support, and insipration. 
  
 
 
v 
 
Table of Contents 
List of Tables ................................................................................................................................ vii 
List of Appendices ....................................................................................................................... viii 
List of Abbreviations ..................................................................................................................... ix 
1 Introduction ............................................................................................................................. 1 
1.1 Background and Significance ............................................................................................. 1 
1.2 Innovation ......................................................................................................................... 10 
1.3 Specific Aims .................................................................................................................... 11 
1.4 Approach ........................................................................................................................... 11 
2 Burden of Depression among Working-Age Adults with Rheumatoid Arthritis .................. 14 
2.1 Abstract ............................................................................................................................. 14 
2.2 Introduction ....................................................................................................................... 15 
2.3 Methods............................................................................................................................. 16 
2.4 Results ............................................................................................................................... 22 
2.5 Discussion ......................................................................................................................... 25 
2.6 Conclusion ........................................................................................................................ 28 
2.7 Acknowledgements and Data User Statement .................................................................. 29 
3 Depression and Treatment Response to Tumor Necrosis Factor Inhibitor Therapy among 
Working-Age Adults with Rheumatoid Arthritis: A Post Regression Non-Linear Decomposition 
Approach ....................................................................................................................................... 36 
3.1 Abstract ............................................................................................................................. 36 
3.2 Introduction ....................................................................................................................... 37 
3.3 Methods............................................................................................................................. 39 
3.4 Results ............................................................................................................................... 44 
3.5 Discussion ......................................................................................................................... 47 
3.6 Conclusion ........................................................................................................................ 50 
3.7 Acknowledgements and Data User Statement .................................................................. 50 
4 Tumor Necrosis Factor Inhibitor Therapy and the Risk of Developing Depression among 
Working Age Adults with Rheumatoid Arthritis .......................................................................... 57 
4.1 Abstract ............................................................................................................................. 57 
4.2 Introduction ....................................................................................................................... 58 
4.3 Methods............................................................................................................................. 60 
4.4 Results ............................................................................................................................... 64 
 
 
vi 
 
4.5 Discussion ......................................................................................................................... 66 
4.7 Acknowledgements and Data User Statement .................................................................. 69 
5 Summary and Conclusion ...................................................................................................... 73 
5.1 Summary ........................................................................................................................... 73 
5.3 Unique Contributions of this Study .................................................................................. 77 
5.4 Strengths and Limitations ................................................................................................. 78 
5.5 Conclusion ........................................................................................................................ 79 
6 References ............................................................................................................................. 80 
7 Appendices .......................................................................................................................... 100 
 
  
 
 
vii 
 
List of Tables 
Table 2.1. Description of Study Sample by Depression among Working-Age (18 - 64 years) 
Adults with Rheumatoid Arthritis, using Medical Expenditure Panel Survey (2009, 2011, 2013 
and 2015) ……………………………………………………………………………………… 30 
Table 2.2. Clinical Outcomes Associated with Depression among Working-Age Adults with 
Rheumatoid Arthritis, Medical Expenditure Panel Survey (2009, 2011, 2013 and 2015) ........ 32  
Table 2.3. Humanistic Outcomes (Health-Related Quality of Measures) by Presence of 
Depression among Working Age Adults with Rheumatoid Arthritis, using Medical Expenditure 
Panel Survey (2009, 2011, 2013 and 2015) ………………………………………………....... 33 
Table 2.4. Economic Outcomes by Presence of Depression among Working Age Adults with 
Rheumatoid Arthritis, Medical Expenditure Panel Survey (2009, 2011, 2013 and 2015) ........ 34  
Table 3.1. Description of Working-Age Adults with Rheumatoid Arthritis initiated on TNFi by 
Depression Status During Baseline, using QuintilesIMS Real-World Data Adjudicated Claims 
Database, 2009-2015 .................................................................................................................. 51 
Table 3.2. Components of the Algorithm for TNFi Response Status at 1 year after TNFi 
Initiation Working-Age Adults with Rheumatoid Arthritis initiated on TNFi by Depression 
Status, using QuintilesIMS Real-World Data Adjudicated Claims Database, 2009-2015 ......... 53 
Table 3.3. Adjusted Odds Ratios (AOR) and 95% Confidence intervals (CI) from Separate 
Logistic Regressions on Response to TNFi by Depression Status Working-Age Adults with 
Rheumatoid Arthritis Initiated on TNFi, using QuintilesIMS Real-World Data Adjudicated 
Claims Database, 2009-2015 ………………….......................................................................... 54    
Table 3.4. Contribution of Individual Characteristics to the Observed Difference in TNFi 
Treatment Response Rate by Depression Status Working-Age Adults with Rheumatoid Arthritis 
Initiated on TNFi, using QuintilesIMS Real-World Data Adjudicated Claims Database, 2009 – 
2015 …………………................................................................................................................. 56    
Table 4.1. Components of the Algorithm for TNFi Response Status at 1 year after TNFi 
Initiation …………………………………………………………………………….................. 70 
Table 4.2. Selected Baseline Characteristics of TNFi Responders vs. TNFi Non-Responders.. 71 
Table 4.3. Adjusted Odds Ratio and 95% Confidence Intervals of Selected Significant Variables 
from Logistic Regression on Newly Diagnosed Depression among Working-Age Adults with RA 
initiated on TNFi, using QuintilesIMS Real-World Data Adjudicated Claims Database .......... 72  
  
 
 
viii 
 
List of Appendices 
Appendix 7.1. Chapter 2. Description of Study Sample Working-Age (18 to 64 years) Adults 
with Rheumatoid Arthritis, using Medical Expenditure Panel Survey (2009, 2011, 2013 and 
2015) ……………………….........................……………………………………………….. 100 
Appendix 7.2. Chapter 4. Baseline Characteristics of Working-Age (18 to 62 years) RA Patients 
Initiated on TNFi therapy from QuintilesIMS RWD Adjudicated Claims Database ............. 102  
Supplemental Figure 7.1.1. Chapter 3. Flow Diagram of Study Cohort .............................. 104  
Supplemental Figure 7.1.2. Chapter 4. Flow Diagram of Study Cohort .............................. 105 
 
  
 
 
ix 
 
List of Abbreviations 
AHRQ Agency for Healthcare Research and Quality 
ADL Activities of Daily Living 
AOR Adjusted Odds Ratio 
AUC Area Under the Curve 
CI Confidence Interval 
CRP C-Reactive Protein 
COL Column 
DAS-28 Disease Activity Soring in 28 joints 
ED Emergency Department 
FDA Food and Drug Administration 
GLM Generalized Linear Model 
HMO Health Maintenance Organization 
HRQOL Health Related Quality of Life 
OOP Out-of-Pocket 
OR Odds Ratio 
IADL Instrumental activities of daily living 
ICD-9-CM International Classification of Diseases, Ninth Revision, Clinical Modification 
IL-1 Interleukin-1 
IL-6 Interleukin-6 
IPTW Inverse Probability of Treatment Weighting 
MEPS Medical Expenditure Panel survey  
MCS Mental Component Summary 
PCS Physical Component Summary 
PDC Proportion of Days Covered 
PPO Preferred Provider Organization 
ROC Receiver Operating Characteristic 
SD Standard Deviation 
SE Standard Error 
SF-12 Short-Form Health Survey 
SIG Significance 
TNFi Tumor Necrosis Factor Inhibitor 
US United States 
USD United States Dollars 
Wt Weighted 
 
  
 
 
1 
 
CHAPTER 1 
1 Introduction 
1.1 Background and Significance 
Epidemiology of RA  
Rheumatoid Arthritis (RA) is the most prevalent immune mediated arthritis affecting 
nearly 1.5 million adults in the United States (US) 1. The prevalence of RA in the U.S. general 
population aged 18 years or older is  0.72% 1. Among the commercially insured adult population, 
the prevalence of RA ranges from 0.41% to 0.54% 2. RA disproportionately affects women with 
more than 75% of RA patients being women3. The lifetime risk of developing RA is 4% for 
women and 3% for men in the US 4.    
The clinical burden can be measured by mortality, disease activity, pain, fatigue, and the 
high prevalence and incidence of other physical and mental health conditions 5-7. Other clinical 
outcomes such as functional status are worse in RA patients as compared to the general 
population as well as those with osteoarthiritis, psoriatic arthritis and ankylosing spondylitis7. 
The inflammatory and immune pathophysiology of RA can also lead to the high 
prevalence of  other chronic conditions 8. Other chronic physical and mental health conditions 
that are most prevalent among patients with RA include hypertension (47.5%), mental health 
conditions (36%), pulmonary diseases (25.5%), endocrine problems (20.3%), cardiovascular 
diseases (18.8%), and gastrointestinal disorders (15.4%) 9. A typical patient with RA has 2 
additional chronic conditions and the burden of chronic conditions increase with increase in the 
severity of RA, duration of RA and age 10. The presence of other chronic conditions can increase 
the risk of mortality and morbidity among RA patients relative to the general population 11. 
Depression in RA 
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Of all the chronic conditions that can co-exist or develop in RA patients, depressive 
disorders deserve special attention because of the special pathophysiology between RA and 
depression.  
Link between RA, Inflammation and Depression  
Patients with RA may have high prevalence and incidence of depression because of the 
heightened level of systemic inflammation underlying the pathogenesis of RA. One study done 
in 218 RA outpatients, demonstrated a significant association between depression severity and 
level of inflammatory marker C-reactive protein (CRP) even after adjustment of RA severity, 
indicating the potential role of inflammation in the pathogenesis of depression12. In addition, 
some studies have also shown that administration of pro-inflammatory cytokines leads to the 
development of depressive symptoms among individuals without pre-existing depression 13,14.  
Prevalent Depression in RA   
A meta-analysis of 72 studies that included 13,189 RA patients, reported that the prevalence 
of major depressive disorders in RA patients was 16.8% (versus 6.7% in general population) 15. 
The same meta-analysis also reported the presence of depressive symptoms in 38.8% of RA 
patients measured using Patient Health Questionnaire (PHQ-9) and 34.2% of RA patients 
measured using Hospital Anxiety and Depression Scale (HADS)15. An inverse relationship was 
found between the presence of depression and age among RA patients indicating a higher 
prevalence of  depression among the younger as compared elderly population with RA15. 
Incident Depression in RA 
One longitudinal study conducted on 4,187 RA patients in the U.K found that almost 30% of RA 
patients developed depression within 5 years of RA onset, 16. The incidence of depression in RA 
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is 74% higher than the general population17. The lifetime risk of developing depression in RA is 
2 times higher in RA patients as compared to the general population18.  
Bidirectional Relationship between RA and Depression  
A bidirectional relationship between RA and depression has been reported; RA increases 
the risk of depression and the onset of depression may also predict increasing severity, pain and 
disease activity in RA19,20. A recent study found that the onset of RA increased the hazards of 
depression onset by 69% and the onset of depression increased the hazards of RA by 65%, even 
after adjusting for age and sex 20. Another cohort study also reported similar bidirectional 
relationship between depression and RA even after adjusting for the genetic risk for depression 
and RA21. 
Disease Burden of Depression in RA 
Clinical Burden: Mortality and Morbidity  
As compared to RA patients without depression, RA patients with depression have poorer 
survival. For example, one study on 1290 outpatients with RA found that prevalent depression 
increased mortality risk by more than 2 folds in RA patients even after adjusting for 
sociodemographic factors, comorbidities and RA severity22. In particular, the risk of 
cardiovascular morbidities such as myocardial infarction and burden of atherosclerosis is 
significantly increased among RA patients with depression as compared RA patients without 
depression 23,24. A retrospective cohort study of 15,634 RA patients, revealed that the presence of 
depression in RA was associated with a 40% increase in myocardial infarction even after 
controlling for sociodemographic and other risk factors 23. Another longitudinal cohort study on 
195 RA patients, depressive symptoms were associated with 3.4 times increase in atherosclerotic 
 
 
4 
 
burden 24. Strong associations with depression and suicidal ideation in RA patients is also well 
documented in literature 25-27. 
Depression can negatively affect clinical remission and disease activity in RA patients28-
30. Depressive symptoms at baseline in RA patients has been reported as an independent 
predictor of disease activity in RA patients even after adjusting for the demographic factors, RA 
duration and severity31. A descriptive study done on 159 RA patients in the United Kingdom 
(UK) reported that persistent depression was associated with RA disease activity32. Presence of 
depression can lead to a significant increase in RA severity.  Matcham et.al., measured increase 
in Disease Activity Score in 28 joints (DAS28) and reported that depression significantly reduces 
the likelihood of clinical remission of RA28.  
Most RA patients experience pain and fatigue due to the disease 33.  The pain severity can 
be exacerbated by the presence of depression and increase in pain severity among RA patients34. 
A systemic review of 29 studies on RA patients found that depression was the most consistent 
predictor of fatigue in RA patients.  
Humanistic Burden 
RA by itself exerts a negative influence on all aspects of health related quality of life 
(HRQOL) such as physical functioning, limitations due to physical function, and bodily pain 7,35. 
One recent study in 1,324 RA patients, showed that with the availability of improved treatment 
options for RA, although the disease activity in RA has reduced by half from 1996 to 2014, 
disability scores and quality of life outcomes remained unchanged36. It is now widely recognised 
that RA affects several aspects of an individual’s life such as work capacity, financial status, 
social relationships, physical and psychological well-being6,37. For example, one panel study on 
548 RA patients in the U.S. reported that 68.4% of RA patients had problems with at least one 
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activity of daily living; while 91.4% of RA patients had problems with at least one committed 
activities of living such as paid work and household responsibilities; and 92.5% of RA patients 
had problems with at least one discretionary activities such as socializing, leisure activities and 
exercise38. In another longitudinal study on 5,384 RA patients done in the U.S., one-fourth, one-
third and half of RA patients respectively experienced permanent work disability in 3 years, 10 
years and 25 years of disease duration 39. 
The present of depression significantly adds to the humanistic burden in RA patients; it 
worsens the HRQoL 40,41 in both physical and mental health domains (42. One longitudinal study 
on 307 RA patients showed that depressive symptoms were a more important predictor of 
HRQoL than disease activity or radiographic damage in RA 43.  
Economic Burden  
The economic burden associated with RA is substantial due to the high costs of medical 
care and productivity loss due to absenteeism and loss of employment. In the US, the aggregated 
total incremental direct medical costs associated with RA was $22.3 billion (2008 USD) 44. The 
national indirect costs associated with RA due to missed work days were $252 million annually 
45.  A review of studies on the indirect economic burdent of RA concluded that RA was 
associated with loss of work productiivty46. 
Depression can exacerbate the direct and indirect economic burden in RA patients 
beyond that required for depression treatment. One study has reported that the presence of 
depression was associated with increases in RA-related hospitalizations and outpatient visits47.  
There could be additional economic burden of depression in RA due to medication non-
adherence.  For example, RA patients with depression are less likely to be adherent to treatment 
regimens 48. Such non-adherence may be associated with considerable increase in disability, 
 
 
6 
 
reduced quality of life, and poor clinical remission, which can lead to higher economic burden 
among adults with RA and depression compared to RA patients without depression.  
However, no recent study in the US has done a comprehensive analysis of the 
incremental economic, clinical and humanistic burden of depression among RA patients.  In fact, 
an expert review on depression among adults with arthritis concluded that more research is 
needed in this area 49. 
Importance of RA and Depression in working-age adults  
Such studies are especially important among individuals of working-age for several 
reasons: the prevalence of depression in this population is higher than older adults; the onset of 
RA typically begins during the most productive mid-life years, between the ages 30 and 60 
years50. Similarly, depression also affects individuals during the prime working years of lives, 
between the ages 24 and 44 51. Both RA and depression are associated with substantial disability. 
One-third of RA patients experience permanent work disability in 3 years, 10 years and 25 years 
of disease duration 39. Depression is also considered as a leading cause of disability among 
working age adults and is associated with substantially reduced work performance due to missed 
work days, presenteeism and premature loss of employment and decrease in income 52,53.  Such 
disabiilties can lead to high productivity losses. For example, nearly 60% of adults with RA may 
be working at the time of onset (with RA may be employed 54.  A systematic review of literature 
on productivity losses in RA patients concluded that although methodologies and costs vary 
across studies the loss represent real cost to both employers and RA patients 46. 
Therefore, it is important to have a more comprehensive understanding of the effect of 
depression on clinical outcomes (e.g. pain-related interference, treatment response to 
antirheumatic therapies), humanistic outcomes (e.g. health related quality of life), economic 
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outcomes (e.g. medical costs, lost wages due to missed work) among working-age adults with 
RA.  This leads to the rationale for Aim1, which estimated the incremental clinical burden (pain 
related interference with normal work), humanistic burden (health related quality of life) and 
direct and indirect economic burden (healthcare costs, missed work days, lost wages due to 
missed work days) associated with depression among working-age RA patients. 
Depression and Treatment of RA 
Since 1997, the treatment of RA has undergone vast changes with the introduction of the 
biological response modifiers, also called biological disease-modifying anti-rheumatic drugs (b-
DMARDs)55. These are genetically engineered large protein molecules that block the activity of 
inflammatory cytokines such as TNF-α, Interleukin-1 (IL-1), Interleulin-6 (IL-6) or cell surface 
receptor molecules such as Janus Kinase56. Currently FDA approved biologics for the treatment 
of RA include five TNF inhibitors (Etanercept, Infliximab, Adalimumab, Certolizumab pegol, 
Golimumab), IL-1 inhibitor (Anakinra), T-cell co-stimulation blocker (Abatacept), B cell 
targeted therapy (Rituximab), IL-6 inhibitor (Tocilizumab) and Janus Kinase inhibitors 
(Toficitinib)(Singh, Saag et al. 2016). Biologic agents are highly effective in slowing the rate of 
long-term structural damage, reducing RA related symptoms, improving physical functioning, 
quality of life, work and productivity and reducing comorbidities56. Furthermore, the clinical 
response to biologics are usually rapid and takes place within days or few weeks of initiating 
therapy55. 
Depression and Tumor Nectrosi Factor Inhibitor Therapy in RA 
Tumor Necrosis Factor inhibitor (TNFi) biologics are recommended as first line biologic 
therapy for RA patients with moderate to severe disease who failed therapy with conventional 
DMARDS such as methotrexate, sulfasalazine and hydroxychloroquine 57. Several randomized 
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controlled clinical trials have proven the high efficacy of TNFi in RA patients after treatment 
failure with conventional DMARDs such as Methotrexate58-60. A recent analysis of US 
prescribing patterns reported an increase in biologic use from 3% of patients in 1999 to 26% in 
2006 61. The prescribing rate of biologics for RA increased by nearly 9 folds from 3% of RA 
patients in 1999 to 26% of RA patients in 2006. A study on commercially insured RA patients 
have found that nearly one-quarter of patients with incident RA are prescribed TNFi therapy 
within 1.75 years after diagnosis 62. 
However, very few studies have evaluated the effect of depression on treatment response 
to particular antirheumatic therapies such as TNFi. One longitudinal cohort study on 166 RA 
patients treated with TNFi in the UK showed that depressive symptoms were significantly 
associated with the discontinuation of TNFi therapy48. However, these studies assessed 
depression as one of the independent variables within a multivariate framework and did not 
evaluate the extent to which each of the individual level variables such as demographics and 
clinical factors in RA patients contributes to the difference in treatment response to TNFi by 
depression status.  
This leads to the rationale of the second aim, which evaluated the effect of depression on 
treatment response to TNFi among working age RA patients who are cared for in routine clinical 
practice. In addition, a post-regression decomposition approach was adopted to explain factors 
that may contribute to difference in the treatment response to TNFi by depression status. 
Tumor Nectrosi Factor Inhibitor Therapy in RA and Risk of Depression  
There has been a growing interest in examining whether anti-inflammatory therapies may 
have beneficial effect in reducing depression among all individuals63 because of the role of 
inflammation in depression and many medical conditions64 and specifically in patients with 
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RA65. A meta-analysis of 14 randomized-controlled trials (RCTs) including 6,262 participants 
revealed that non-steroidal anti-inflammatory drugs (NSAIDS) are significantly more effective 
as compared to placebo in reducing depressive symptoms 66. Other powerful anti-inflammatory 
drugs such as inflammatory cytokine inhibitor biologic therapies, including tumor necrosis factor 
inhibitor (TNFi) are also being studied for their potential anti-depressant effect. Another recent 
meta-analysis of 7 RCTs including 2,370 participants reported a significantly higher 
antidepressant effect of biologic therapies such as TNFi as compared to placebo 65. These 
observations have strengthened the hypothesis that inflammation plays a crucial role in the 
pathogenesis of depression and suppression of inflammation with powerful anti-inflammatory 
drugs such as TNFi in patients suffering from inflammatory arthritis such as RA may have a 
potential beneficial effect in reducing depression. 
Findings from the above mentioned studies sugest that anti-inflammatory effect of TNFi 
therapy may have spillover effects and may reduce the risk of depression in RA patients67,68. 
However, not all RA patients respond to TNFi therapy. Infact, in real-world clinical practice, 
only one-third of RA patients respond to TNFi therapy(Curtis, Schabert et al. 2014). Therefore, 
the beneficial effect of TNFi on depression may be limited to RA patients who respond to TNFi 
therapy. To date, no real world clinical study has evaluated the effect of treatment response to 
TNFi on the risk of developing depression in RA patients.  
This leads to the rationale of the aim 3, which examined the effect of treatment response 
to TNFi therapy on the risk of developing depression among working age commercially insured 
RA patients 
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1.2 Innovation 
a) Comprehensive analysis of the illness burden of depression among a nationally 
representative sample of working-age RA patients with depression: This is the first study 
to conduct a comprehensive analysis of the clinical, humanistic and economic burden 
associated with depression among working-age adults with RA. 
b) Use of a novel claim based algorithm to measure treatment response to TNFi: The 
algorithm to measure treatment response to biologic drugs in RA developed by Curtis et al. 
using claims data has been validated and accurately captures the clinical response to TNFi. 
This novel algorithm enables us to assess treatment response to TNF inhibitors among RA 
patients who are cared for in real world practice setting utilizing data that are readily 
available from claims. Till date, this algorithm has been only used for descriptive analysis of 
the comparative effectiveness of various biologics in RA. Our study is the first study to use 
this algorithm to model treatment response while controlling for various clinical and 
demographic factors. 
c) Application of econometric techniques to identify difference in characteristics between 
patients with and without depression that explain disparity in treatment response 
between the two groups: This is the first study to examine the contribution of various 
individual characteristics of RA patients to the observed gap in the treatment response rate 
between those with depression versus those without depression from a population based 
perspective. 
d) Protective Effects of TNF inhibitors in reducing the risk of depression in RA patients:  
This is the first observational study to use a nation-wide database of commercially insured 
working-age RA patients to evaluate the association between response to TNFi and risk of 
newly-diagnosed depression.  
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e) Use of a nationally representative data of commercially insured RA patients: One of the 
main advantages of using the IMS Pharmetrics claims data for this study is the availability of 
a large, diverse, nationally representative population of working age commercially insured 
RA patients. 
1.3 Specific Aims 
AIM 1:  Evaluate the incremental illness burden associated with depression among working-
age RA patients.  The illness burden domains are: Clincial - pain related interference with 
normal work; Humanistic - health related quality of life and Economic burden -healthcare 
costs, missed work days, lost wages due to missed work days.  
Hypothesis:  RA patients with depression will have a higher clinical, humanistic and 
economic burden as compared to RA patients without depression. 
AIM 2:  Examine the association between depression and treatment response to TNFi among 
working age commercially insured RA patients. 
Hypothesis: RA patients with depression will be less likely to respond to TNFi therapy as 
compared to RA patients without depression. 
AIM 3:  Investigate the effect of treatment response to TNFi therapy on the risk of newly 
diagnosed depression among working-age commercially insured RA patients. 
Hypothesis: RA patients who respond to TNFi therapy will be less likely to develop 
depression as compared to RA patients who does not respond to TNFi therapy. 
1.4 Approach  
Conceptual Framework  
Aim 1 and Aim 2: The conceptual framework for this study is adapted from the 
Andersen’s Expanded Behavioral Model 69 which posits that healthcare utilization by an 
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individual is a function of predisposing factors (e.g. age, sex ), enabling factors (e.g. the type of 
plan, the calendar year of TNF inhibitor initiation), need factors (e.g. chronic conditions, RA 
severity, baseline health service utilization) and external environment factors (e.g. geographical 
region). As the effectiveness construct was operationalized based on prescription drug 
utilization, the Andersen’s Behavioral Model was an appropriate conceptual model for selecting 
the independent variables in our study. The predisposing factors represents the individual 
characteristics that predict the propensity for use of healthcare services. The enabling factors 
represent the factors that enable an individual to gain access to healthcare services. The need 
factors are those characteristics that define an individual’s health status. The external 
environment represent the environmental and geographical factors that influence an individual’s 
health service utilization. 
Aim 3: The conceptual framework for this study was adapted from the determinants of a 
health and chronic disease model proposed by Wilkinson and Marmot 70. This model delineates 
the relationship between community resources, access to care variables, individual physical 
make-up, biological risk factors, and treatment factors that affect the incidence of chronic 
conditions. 
Data Sources 
 To accomplish the study objectives, we used data from multiple sources.  To estimate the 
incremental clinical, humanistic, and economic burden of depression in RA patients (aim 1), we 
selected the nationally representative survey of the US civilian non-institutionalized households, 
namely the Medical Expenditure Panel survey (MEPS).  The MEPS collects information on 
demographic characteristics, medical conditions, health status, health-related quality of life, 
utilization of health care services, charges and payments, access to care, health insurance 
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coverage, income, education, employment and missed work days of all members in the selected 
households.  
To analyze the interaction between depression and treatment response (aims 2 and 3) we 
used IMS PharMetrics Plus claims data for the period October 1, 2009 to September 30, 2015. 
PharMetrics Plus is an integrated claims database that includes enrollment, medical and 
pharmacy claims information for more than 95 million enrollees of commercial plans across the 
US. The data includes the records of 90% of hospitals, 80% of doctors and 85% of large 
companies in the US. This database also records enrollee’s demographics (year of birth, gender, 
geographic region), plan type (health maintenance organization, preferred provider organization), 
payer type (commercial, self-insured), prescription drug information and considered nationally 
representative of commercially insured individuals less than 65 years of age in the US. 
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CHAPTER 2 
2 Burden of Depression among Working-Age Adults with Rheumatoid Arthritis  
2.1 Abstract 
Objective: This study estimated the excess clinical, humanistic, and economic burden 
associated with depression among working-age adults with Rheumatoid Arthritis (RA). Methods: 
A retrospective cross-sectional study was conducted among working-age (18 to 64 years) RA 
patients with depression(N=647) and without depression(N=2,015) using data from the 
nationally representative Medical Expenditure Panel Survey for the years 2009, 2011, 2013 and 
2015. The clinical outcome was: level of pain interference with normal work and any functional 
limitations; humanistic outcomes were: health-related quality of life (HRQoL) measures from the 
12-item short-form health survey(SF-12-V2); and economic outcomes were: direct total annual 
healthcare expenditures, out-of-pocket spending, and burden, unemployment, the number of 
annual missed work days and lost wages due to missed work days. Counter-factual recycled 
prediction method was used to assess the incremental burden associated with depression.  
Results: Overall, 25.8% had depression.  In adjusted analyses, adults with RA and depression 
compared to those without depression were significantly more likely to have pain interference 
with normal work (severe pain: AOR=2.22; 95% CI=1.55, 3.18), any functional limitations 
(AOR=2.17; 95% CI=1.61, 2.94), lower mental health HRQoL scores. Adults with RA and 
depression had significantly higher annual healthcare expenditures ($14,752 vs. 10,541, p 
<.001), and out-of-pocket spending burden.  Adults with RA were more likely to be unemployed 
and among employed adults, those with depression had a significantly higher number of missed 
work days annually and higher lost annual wages due to missed work days. Conclusions: This 
study highlights the importance of effectively managing depression in routine clinical practice of 
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RA patients to reduce pain, any functional limitations, improve quality of life, lower direct and 
indirect healthcare costs. 
2.2 Introduction  
Rheumatoid Arthritis (RA) is one of the most debilitating chronic conditions, with the 
onset often occurring during the prime working years of lives, between the ages 20 and 40 years 
50.  Individuals with RA experience substantial pain and RA causes permanent work disability in 
more than one-third of affected patients within 10 years of onset 39.  Such pain and disabilities 
associated with RA may contribute a higher prevalence of depression in individuals with RA 
compared to healthy controls 71. An expert review of depression in arthritis reported that the 
prevalence of depression in adults with RA can be as high as 66.2% 49.  A systematic review and 
meta-analysis of 72 studies estimated the prevalence rate to be 16.8% 72. 
The disease burden of depression in RA can be substantial because depression can 
worsen survival 73 and increase morbidity in terms of disability, health-related quality of life 
(HRQoL), RA disease activity 28 and pain 12. Depression in RA can also increase healthcare 
resource utilization 47,74, which can lead to high health care expenditures for both insurance 
payers and patients and families.  As depression in RA can aggravate disability, an individual 
may also suffer economic losses due to work inability or even experience economic losses due to 
missed work days. Although not specific to RA, one study estimated that 6.9 million working-
age adults reported arthritis-attributable work limitation75.  One can speculate that depression can 
worsen the work-limitation because the presence of depression along with any chronic physical 
condition more than doubles the likelihood of work absenteeism as compared to the presence of 
any chronic physical condition without depression 76 
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However, to date, no published study in the US has done a comprehensive analysis of the 
humanistic and economic burden associated with depression among RA patients, particularly 
among working-age adults. In fact, a recent review highlighted the significant knowledge gap in 
estimating the disease burden of depression in adults with arthritis49.  Although there has been a 
handful of studies on the association between depression and HRQoL among adults with RA, 
most of these studies have been conducted outside the US 77,78  or only among women in a 
specific setting79. One US study used a cross-sectional design and examined the relationship 
between depression and disability, HRQOL in the US with data from 2011 he 2011 Behavioral 
Risk Factor Surveillance System80. However, this study included all forms of arthritis and did not 
focus on RA.  Again, only one study using 2006 commercial claims data in the U.S., found that 
RA patients with depression had a significantly higher adjusted annual healthcare costs as 
compared to RA patients without depression ($12,225 vs. $11,404)81. However, this study was 
based on commercially insured RA patients and may not be representative of the U.S. national 
population. Furthermore, this commercial insurance data did not include certain patient 
characteristics which are important confounders of healthcare costs such as race, education and 
income level.  
Therefore, the objective of this study is to examine the incremental burden of depression 
on the clinical, humanistic and economic outcomes among working-age adults with RA. 
2.3 Methods 
Study Design 
A retrospective cross-sectional study design with data from a nationally representative 
sample of working-age adults (18-64 years) was used. 
Data Source 
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We used data from the Medical Expenditure Panel Survey (MEPS), an annual household 
survey of the non-institutionalized civilian population in the U.S. Information on demographic 
characteristics, medical conditions, health status, utilization of health care services, charges and 
payments, access to care, health insurance coverage, income, education, employment and missed 
workdays of the participants in the survey were extracted from the household component of 
MEPS. We pooled four years of data (2009, 2011, 2013, and 2015) to have sufficient sample 
size, and used data from alternate years to avoid including two observations per individual.  
Furthermore, a question related to the type of arthritis was available in these years. Indeed, 
MEPS recommends pooling of data to increase sample size and it is a common practice in 
published literature with MEPS data82. 
Study Sample 
The study sample (N = 2,662) consisted of working-age (18-64 years) who were 
diagnosed with RA and who were alive during the study period (2009, 2011, 2013, and 2015). 
RA was identified from the priority condition enumeration section.  In this section, respondents 
were queried whether an individual in the household has ever been told by a doctor or other 
health professional that she/he had arthritis and type of arthritis (RA versus osteoarthritis).  We 
also identified RA from medical condition file with the clinical classification code (202). 
Medical conditions were reported by the respondents if they sought treatment for the condition, 
or if the condition resulted in disability, or if the condition was bothersome.  The responses were 
recorded as texts, and these texts were translated into International Classification of Diseases, 9th 
Edition, Clinical Modification (ICD-9-CM) codes by professional coders. In addition, MEPS 
data provides clinical classification codes, which are aggregated ICD-9-CM codes into clinically 
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meaningful categories that group similar conditions (Agency for Healthcare Research and 
Quality). 
Conceptual framework  
The conceptual framework for this study was adapted from the Andersen’s Expanded 
Behavioral Model which posits that health services utilization and outcomes of an individual is a 
function of predisposing factors (e.g., age, sex, and race), enabling factors (e.g. marital status, 
education and poverty status), need factors (e.g. chronic conditions, health status), and personal 
health practices (e.g. physical activity, obesity and smoking)69. 
Measures 
Clinical Outcomes:   
Pain Interference with Normal Activities: Based on a self-administered single-item 
question, pain interference with normal activities during the past four weeks among the 
household respondents was measured.  The answers were recorded on a 5-point Likert scale 
during the past 4 weeks. In MEPS, pain was reported on a 5-point scale: 1) Not at all, 2) A little 
bit, 3) Moderately, 4) Quite a bit, and 5) extremely. For purposes of this study we group pain 
categories as follows: 1) Not at all/little bit; 2) Moderate; 3) Severe (quite a bit/extremely). Self-
reported pain from MEPS has been used in published literature to estimate the cost of pain 83. 
There were 42 individuals (5.9%) in the depression group and 140 individuals (6.6%) in the no 
depression group with missing data on pain inference variable.   These individuals were not 
included in the analysis. 
Any Functional Limitations: This variable summarizes whether an individual had any 
limitations in instrumental activities of daily living (IADL) (e.g. shopping, cooking, using phone, 
paying bills, taking medications, driving, doing laundry, or going shopping), activities of daily 
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living (ADL) (e.g. bathing, dressing, grooming, mouthcare, toileting, eating), functional 
(walking, climbing stairs, grasping objects, reaching overhead, lifting, bending or stooping, or 
standing for long periods of time) or activity limitations (work, housework, or school).  
Humanistic Outcome:  Health-related Quality of Life  
HRQoL was measured by the generic Short-Form-12 Version 2 (SF12-V2) summary 
scores. The SF12-V2 is a generic multipurpose survey with 12 questions, which encompass eight 
domains (role physical, role emotional, physical function, social function, mental health, vitality, 
pain, and general health).  These questions are designed to provide summary measures of overall 
HRQoL of an individual. The Mental Component Summary (MCS) score was derived from the 
responses to the items in the domains: vitality, social functioning, role-emotional (limitations in 
work and daily activities because of emotional problems), and mental health. The Physical 
Component Summary (PCS) score was derived from the responses to the items in the domains: 
physical functioning, role-physical, bodily pain, and general health. Both MCS and PCS scores 
ranged from 0 to 100, with higher scores representing better self-reported health and better 
HRQoL related to mental or physical health84.  
Economic Outcomes:  Direct Healthcare Expenditures  
Total healthcare expenditures: In the MEPS, expenditures are defined as the sum of 
direct payments for care provided during the year.  The direct payments include twelve sources 
of payment categories such as out-of-pocket by patient or families, Medicare, Medicaid, Private 
insurance, Veteran Administration, worker’s compensation, and others. Total annual per person 
healthcare expenditures were calculated as the sum of inpatient, outpatient, emergency, dental, 
home health, vision, prescription drugs and other medical supplies. All expenditures were 
inflation adjusted to 2015 US dollars (USD) using consumer price index for medical services 
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from the bureau of medical services.   
Total out-of-pocket spending burden by patients and families: We also estimated the total 
out-of-pocket spending on healthcare by the respondent and/or family.  These included annual 
deductibles, copayment, and coinsurance for services and payment for services that were not 
covered by health insurance. We calculated out-of-pocket spending burden as the ratio of out-of-
pocket healthcare expenditures to personal income 85, which varied from zero to 100.  Based on 
published literature, we defined spending 10% or more of personal income on health care as high 
out-of-pocket spending burden 86. 
Economic Outcomes:  Indirect Healthcare Burden  
Unemployment (i.e. labor market outcome). In the MEPS, employment section covers 
questions about each person's employment or self-employment status. Based on these questions, 
we classified individuals were currently unemployed.  
Missed work days were measured whether individuals lost a half-day or more from work 
because of illness, injury, or mental or emotional problems during the year and how many 
workdays were lost.  This was calculated only for employed adults. 
Lost wages for each individual were calculated by multiplying missed work days with an 
average daily wage of each individual. All wages were adjusted to 2015 general consumer 
inflation rates derived from the bureau of labor statistics. 
Key Explanatory Variable 
Depression (yes/no): Depression was identified based on the clinical classification code 
“657”, which included both depressive disorders and bipolar disorders. 
 Other Explanatory Variables 
Predisposing characteristics were sex (male, female), race/ethnicity (Whites, African-
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American, other racial minorities) and age in years (18–39, 40-49 and 50-64). Enabling factors 
comprised marital status (married, widow, separated/divorced, never married), family poverty 
status (not poor, poor), health insurance status (public, private) and usual source of care (yes, 
no). Need Factors included having a chronic condition other than RA from a list of eight 
conditions: asthma, cancer, chronic obstructive pulmonary disease, diabetes, heart disease, 
hypertension, stroke, and thyroid), anxiety, perceived physical health status (excellent/very good, 
good and fair/poor) and perceived mental health status (excellent/very good, good and fair/poor). 
Personal health practice factors included obesity (obese and not obese), smoking status (current 
smoker, other, missing) and exercise (“yes” and “no” exercise).  
Statistical Analyses  
A variety of statistical analyses were used based on the measurement of the outcome 
variables. The unadjusted relationships between the presence of depression and categorical 
variables and outcomes (pain interference with activities, employment, and OOP burden) were 
assessed with chi-square tests. Unadjusted differences in continuous outcomes (PCS, MCS, all-
cause healthcare expenditures, out-of-pocket spending by the patients and their families) by 
depression were tested with t-tests.  Multinomial logistic regression was used to analyze the 
association between depression and pain-related interference with normal work after adjusting 
for the predisposing, enabling, need and external environment characteristics. Logistic regression 
was used to analyze the association between depression and binary categorical variables (e.g. any 
limitations, unemployment, out-of-pocket spending burden) after adjusting for covariates. 
Adjusted models for continuous outcomes (expenditures, out-of-pocket expenditures, and lost 
wages) consisted of Generalized Linear Models (GLM). GLM is flexible and can handle 
categorical outcomes, continuous outcomes, and count-data with the appropriate distribution 
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family and a link function. For categorical outcomes, we conducted logistic regression. For 
count-data (e.g. the number of missed work days) we used negative binomial regression.   
Counterfactual prediction technique (Recycled Prediction): We used counterfactual 
recycled prediction, an approach that is gaining attention 87,88 to estimate excess total healthcare 
expenditures, prescription expenditures, missed work days and lost wages attributable to 
depression among working-age adults with rheumatoid arthritis. The recycled prediction 
technique is a preferred approach because it adjusts for differences in characteristics between the 
depression and no depression group by creating counterfactual scenarios. In all recycled 
prediction models, confidence intervals were obtained using 2000 bootstrap replications using 
the percentile method. To account for the complex design of MEPS, we conducted all analyses 
using the survey procedures in Statistical Analysis Software (SAS) version 9.3, Cary, NC, USA 
and the survey design features with STATA 14. As we pooled four years, to get annualized 
weighted numbers, we divided the weights by four, recommended by the MEPS investigators 89 
and used in the published literature 90. 
2.4 Results 
Description of the study sample 
Majority of the study sample was female (64%), white (63%), aged between 50 and 64 
years (61%) and had multi-morbidity (72%).  Only 26% of individuals who perceived 
themselves having excellent or very good physical health and 44.8% reported having excellent or 
very good mental health (See Appendix 7.1). 
Overall, 25.8% of adults with RA reported depression (Table 2.1).  We observed 
significant differences in the rate of depression by predisposing, enabling, need factors, and 
personal health practices except for age, education, and region.  For example, female adults with 
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RA reported a significantly higher rate of depression than their male counterparts (29.6% vs. 
19.1%). The higher rate of depression was also observed among individuals with multimorbidity 
(29.1% vs. 17.4%).   A higher percentage of those who perceived themselves to be poor/fair 
physical health reported depression compared to those in excellent or very good health (38.0% 
vs. 12.4%). 
Clinical Outcomes 
Pain Interference with Normal Activities 
A higher percentage of adults with RA and depression reported severe pain interfering 
with work or other normal activities compared to those with RA and no depression (54.8% vs. 
30.8%) (Table 2.2).  After adjusting for predisposing, enabling, need, personal health practices, 
and external environment factors, adults with depression were 2.2 times as likely to report severe 
pain interference with normal work activities than those without depression (AOR=2.22; 95% 
CI=1.55,3.18). 
Any Functional Limitations 
A significantly higher percentage of adults with RA and depression reported any 
limitations compared to those with RA and no depression (79% vs. 51.1%) (Table 2.2). After 
adjusting or covariates adults with RA and depression were more than 2 times as likely to report 
any functional limitations (AOR=2.24; 95% CI=1.62, 3.10) compared to  adults with RA and no 
depression. 
Humanistic Outcomes 
Adults with RA and depression reported significantly lower HRQoL scores in both 
physical component summary score (35.1 vs 40.2, p<.001) and mental component summary 
score (37.2 vs 48.7, p<.001) compared to adults with RA without depression (Table 2.3).  In 
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adjusted analyses, a significant difference was observed only in the mental domain of the 
HRQoL; the presence of depression was associated with a decrement of 8.72 in MCS scores 
(Table 2.3).  The counterfactual predictions yielded similar differences in MCS (37.19 in adults 
with depression vs. 45.91 in adults without depression, p<.001).  The relationship between 
depression and PCS scores became insignificant after adjustment for the presence of multiple 
chronic conditions.  
Economic Outcomes  
Direct Total Healthcare Expenditures 
In unadjusted analysis, adults with RA and depression had significantly higher annual 
healthcare expenditures ($17,941 vs. $10,064 p<.001).   In the adjusted GLM with gamma 
distribution and log-link, we found that depression was associated with greater total healthcare 
expenditures compared to those without depression (Beta = 0.34, SE = 0.08).  When converted to 
original dollars this represented $14,752 for those with depression and $10,541 for those without 
depression (Table 2.4).  Estimates from counter-factual recycled prediction revealed that 
depression was associated with an excess of $4,212 total healthcare expenditures with 95% CI = 
$4,114, $4,318.   
In unadjusted analysis, patients/families in the RA + depression group spent significantly 
higher amounts out-of-pocket on health care compared to the RA + no depression group ($1,443 
vs. $1,052, p<.001).   In the adjusted GLM with gamma distribution and log-link, we found that 
depression was associated with greater total out-of-pocket healthcare spending compared to 
those without depression (Beta = 0.23, SE = 0.06).  When converted to original dollars this 
represented $1,232 for those with depression and $979 for those without depression (Table 4).  
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Estimates from counter-factual recycled prediction revealed that depression was associated with 
an excess of $253 with 95% CI = $247, 260.   
When high out-of-pocket spending burden was measured as spending greater than 10% of 
income on healthcare, we found that 30.7% of adults with depression and 21.3% of adults 
without depression had high out-of-pocket spending burden.  After adjusting for other factors, 
adults with depression were significantly more likely to have high out-of-pocket spending burden 
(AOR=1.34; 95% CI=1.01, 1.79).  
Indirect Economic Burden   
Labor market outcome (Unemployment), missed work-days and lost wages   
Presence of depression was significantly associated with unemployment among adults 
with RA; 64.1% of adults with depression were unemployed compared to 40.1% adults without 
depression. Even after controlling for other factors mentioned in the methods section, adults with 
RA and depression were 1.55 times as likely as those without depression to be unemployed 
(AOR=1.55; 95% CI=1.14, 2.10). Among employed adults, those with depression had 
significantly higher number of missed work days annually (9 vs. 6, p<0.05) and higher lost 
wages ($813 vs. $571, p<0.05) due to missed work (Table 2.4).  We obtained similar results with 
counterfactual recycled predictions.   
2.5 Discussion 
In this study using a nationally representative sample of community-dwelling US adults, 
one in four working-age adults with RA reported depression. This rate is considerably higher 
compared to the 6.8% rate of depression in the general population in the U.S.51 and higher than 
the pooled depression rate of 16.8% reported by Matcham and collegues72.  The difference in 
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rate can be explained by the differences in time period, study population and instruments that 
were used to identify depression.  
Our study findings indicated the substantial additional clinical burden imposed by 
depression in working-age adults with RA.  These findings have implications for co-management 
of depression and RA. Although not specific to RA, a randomized clinical trial of 1,001 patients 
with concurrent depression and arthritis and seeking care from 18 primary care clinics91 
suggested that collaborative depression care not only reduced depressive symptoms but also 
improved arthritis related outcomes, such as decreasing pain and functional limitations. There is 
some evidence that disease-modifying drugs used to treat RA can have spill-over effects in 
reducing depressive symptoms. For example, depression levels decreased significantly following 
commencement and continuity of rituximab, a B cell-directed therapy, among individuals with 
RA92. Therefore, future studies need to systematically evaluate whether anti-rheumatic treatment 
among individuals with RA can help alleviate depressive symptoms. 
We also observed significant decrements in HRQoL measures, specifically the MCS 
scores. This is not surprising, however, it is important given the strong association between 
patient-reported outcomes and disease activity 93. It has also been suggested that patient-reported 
outcomes such as the HRQoL and other measures in clinical trials and routine clinical practice 
may shed light on variations in treatment response as well as the burden of disease among RA 
adults 93,94.  Our findings suggest that collecting patient-reported HRQoL can be critical in 
assessing disease burden that may not be captured by clinical assessment alone 93. 
Depression in working-age adults with RA was associated with substantial direct and 
indirect economic burden.  For example, the presence of depression more than doubled the 
annual per person total healthcare costs, a number of missed work days and lost wages due to 
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missed work days, even after controlling for predisposing factors, enabling characteristics, need 
factors, and personal health care practices. Although published evidence on the incremental 
economic impact of depression in RA is limited81, our findings are consistent with studies 
assessing the burden of depression on other chronic illness such as diabetes, cardiovascular 
disease and asthma have also reported the synergistic effect of depression in increasing the 
economic burden among individuals with chronic conditions 76,95.  
Our findings on the economic burden of depression in RA patients has important 
implications for the payers as it highlights an opportunity for reducing expenditures in RA 
patients by increasing efforts towards screening and effectively treating depression in RA 
patients. Potential strategies such as improving the integration of mental health services with 
rheumatology practice and facilitating mental health training for rheumatologists.  Future studies 
need to explore whether treatment for depression provides an opportunity to reduce direct 
healthcare expenditures associated with depression in RA patients.  
The study findings have important implications for the employers because depression 
costs U.S. employers more than $31 billion annually due to missed work and decreased work 
performance 96. One study done in the U.S. reported that depression leads to the highest 
reduction in work performance and the highest employer burden relative to any other chronic 
conditions 97.Strategies that employers may adopt to improve mental health in employees include 
organizing workplace health promotion programs and stress management projects, which have 
shown the benefits of prevention and management of depression in workplace98,99. 
To the best of our knowledge, this is the first population-based study that 
comprehensively examined the excess clinical, humanistic and economic burden of depression in 
working-age adults with RA.  Other strengths of this study include the use of nationally 
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representative survey, adjustment of a comprehensive list of confounders such as predisposing 
factors, enabling factors, need factors, and personal health care practices and the use of robust 
statistical techniques such as GLM, and recycled prediction in estimating the incremental costs 
and missed workdays.  
However, the findings of this study should be interpreted considering its potential 
limitations. First, we did not control for the severity and duration of RA and depression as MEPS 
does not contain this information. These factors can be important confounders of both healthcare 
costs and work absence. Second, we have measured productivity loss as missed work days and 
did not consider other kinds of productivity loss such as reduced productivity while at work 
(presenteeism) and loss of employment.  
2.6 Conclusion 
Our findings would provide valuable insights to payers and other decision-makers to 
better understand the economic impact of comorbid depression on working RA patients from 
U.S. societal perspective. It is well-documented that depression in RA patients is often under-
recognized and under-treated in routine clinical practice 32,100. Therefore, our study underscores 
the need for incorporating depression screening and management in the routine clinical 
management of RA in order to offset the substantial incremental costs associated with 
depression. Published evidence has well documented that depression is a treatable condition. 
However, it is still not clear whether depression treatment is equally effective in RA patients as 
compared to those with depression without RA 101. Future studies need to assess the potential 
cost reductions that can be achieved through early detection and more aggressive treatment of 
depression in RA patients. 
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Table 2.1. Description of Study Sample by Depression   
among Working-Age (18 - 64 years) Adults with Rheumatoid Arthritis  
Medical Expenditure Panel Survey (2009, 2011, 2013 and 2015) 
    RA with Depression RA without Depression   
    N Wt. N  Wt Row%  N Wt. N  Wt. Row %  Sig 
All  647    1,476,543  
 
2,015  4,243,456  
  
        
Gender 
      
***  
Female  502    1,083,578              29.6  1,324  2,578,380             70.4    
 
Male  145       392,965              19.1       691    1,665,075                80.9  
 
Race/Ethnicity  
      
***  
White  328    1,058,311              29.4       733    2,537,939                70.6     
African American  157       182,570              18.4       621       807,252                81.6  
 
 
Latino  127       163,752              21.0       512       616,664                79.0  
 
 
Other    35         71,909              20.3       149       281,601                79.7  
 
Age in years 
       
 
18-39 years    98       235,700              24.6       346       720,952                75.4  
 
 
40-49 years  149       328,252              25.8       460       943,419                74.2  
 
 
50-59 years  281       625,767              26.9       799    1,700,525                73.1  
 
 
60-64 years 119       286,824              24.6       410       878,561                75.4  
 
Marital Status 
      
***  
Married  248       641,950             20.7    1,039    2,456,470                79.3    
 
Widow/Separated/Divorced  259       559,609              34.3       586    1,070,571                65.7  
 
 
Never married  140       274,983              27.7       390       716,415                72.3  
 
Education 
       
 
Less than High School  170       263,811              26.2       495       744,015                73.8  
 
 
High School  232       554,459              27.1       707    1,489,505                72.9  
 
 
Missing      4           8,945              20.0          18          35,863                80.0  
 
Poverty Status 
      
***  
Poor  236       414,448              34.1       504       802,320                65.9  
 
 
Not Poor  185       352,687              29.3       490       851,481                70.7  
 
 
Middle Income  141       404,446              24.2       567    1,265,564                75.8  
 
 
High Income    85       304,962              18.7       454    1,324,091                81.3  
 
Insurance Status 
       
 
Private  235       732,981              21.5    1,067    2,678,551                78.5   ***   
Public  345       614,426              38.9       587       965,896                61.1  
 
 
Uninsured    67       129,136              17.7       361       599,008                82.3  
 
Employment 
       
 
Employed  195       529,563              17.2    1,114    2,541,537                82.8   ***   
Not Employed  452       946,980              35.8       900    1,700,303                64.2  
 
Region 
       
 
Northeast    89       202,685              20.6       294       782,095                79.4  
 
 
Mid-west  157       373,157              29.5       366       891,070                70.5  
 
 
South  271       644,003              26.2       919    1,810,392                73.8  
 
 
West  130       256,698              25.3       436       759,899                74.7  
 
(Continued)        
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Table 2.1. Description of Study Sample by Depression   
among Working-Age (18 - 64 years) Adults with Rheumatoid Arthritis  
Medical Expenditure Panel Survey (2009, 2011, 2013 and 2015) 
    RA with Depression RA without Depression   
    N Wt. N  Wt Row%  N Wt. N  Wt. Row %  Sig 
All  647    1,476,543  
 
2,015  4,243,456  
  
        
         
Perceived Physical Health Status 
     
***  
Excellent/very good    72       184,075              12.4       535    1,304,540                87.6    
 
Good  165       443,888              22.2       706    1,557,298                77.8  
 
 
Fair/poor 410       848,580              38.0       774    1,381,618                62.0  
 
Perceived Mental Health Status 
     
***  
Excellent/very good 113 299,418 11.7 995 2,261,378 88.3   
Good 207 489,425 25.1 730 1,460,392 74.9   
Fair/poor 327 687,700 56.9 290 521,687 43.1  
Multimorbidity 
      
*** 
 
RA only  110       278,813              17.4       606    1,327,073                82.6  
 
  Multimorbidity  537    1,197,730              29.1    1,409    2,916,383                70.9    
Anxiety 
      
***  
Yes  259       603,236              53.2       235       531,105                46.8  
 
 
No  388       873,307              19.0    1,780    3,712,351                81.0  
 
Obesity 
   
               ** 
 
Obese  353       763,026              30.3       865    1,758,314                69.7  
 
 
Not Obese  287       689,528              22.4    1,105    2,395,174                77.6  
 
Smoking Status 
      
***  
Current smoker  250       571,504              36.5       448       995,953                63.5  
 
 
Other  355       818,352              21.9    1,400    2,911,573                78.1  
 
Exercise 
      
*** 
 
Yes  190       425,224              18.0       887    1,939,578                82.0  
 
 
No exercise  454    1,039,728              31.3    1,114    2,281,839                68.7  
 
         
Table 2.1 1 
Table 2.1 2 
Note: Based on 2,662 adults with Rheumatoid Arthritis aged between 18 to 64 years, who were alive during the 
calendar year.  Missing data for the following variables (education, obesity, smoking, and exercise) are not 
presented.  
 
Asterisks represent significant group differences by the presence of depression based on chi-square tests.  Weighted 
N and percentages were derived by dividing the person weights by the number of years pooled. 
 
Wt.  Weighted  
 
 *** p < .001;  ** .001 ≤ p < .01; * .01 ≤ p < .05 
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Table 2.2. Clinical Outcome Associated with Depression 
among Working Age Adults with Rheumatoid Arthritis 
Medical Expenditure Panel Survey (2009, 2011, 2013 and 2015)   
 RA + Depression   RA and No Depression  
 
     N   Wt.  
Col. %  
 N   Wt. 
Col. %  
  Sig   
All             605                       1,875                 
Pain Interference with Daily 
Activity 
    
*** 
 
Mild/None 155 29.8 918 51.9 
 
 
Moderate 92 15.4 317 17.3 
 
 
Severe (Extreme/Quite a lot) 358 54.8 640 30.8 
 
Limitations      
 Any Functional Limitations 528 79.0 1,026 51.1 *** 
       
Adjusted Odds Ratio and 95% CI for Depression from 
Multinomial Logistic Regression on Pain Interference with Normal Activity  
Pain Interference with Daily 
Activity 
AOR 95% CI  Sig  
 Mild/None (Reference Group)     
 Moderate  1.37 [0.91, 2.06]   
 Severe  2.22 [1.55, 3.18] ***  
      
Adjusted Odds Ratio and 95% CI for Depression from 
Logistic Regression on Limitations 
Limitations AOR 95% CI  Sig  
 Any Functional Limitations 2.24 [1.62, 3.10] ***  
      
 
Note: Based on 2,662 adults with Rheumatoid Arthritis aged between 18 and 64 years, who were alive during the 
calendar year.  Adjusted multinomial logistic regression controlled sex, race/ethnicity, age, region, marital status, 
education, family poverty status, health insurance, physical health status, mental health status, anxiety, 
multimorbidity, obesity, physical activity and smoking. Asterisks represent significant group differences by the 
presence of depression.  
 
*** p < .001; ** .001 ≤ p < .01; * .01 ≤ p < .05.  
 
Col: Column; Wt.: Weighted  
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Table 2.3. Humanistic Outcomes (Health-Related Quality of Measures) by Presence of Depression  
among Working Age Adults with Rheumatoid Arthritis 
Medical Expenditure Panel Survey (2009, 2011, 2013 and 2015)   
 RA + Depression   RA and No 
Depression  
 
     Wt. Mean SE Wt. Mean SE 
 
  Sig   
All             N =647                        N =2,015                 
Physical Component Summary 
Score  
     
  
35.07 0.89 40.18 0.47 *** 
Mental Component Summary  
Score  
     
  37.20 0.77 48.74 0.37 *** 
       
Fully-Adjusted Model:  Parameter Estimates and Standard Errors for Depression  
Ordinary Least Squares Regression  
Mental Component Summary Score  
  Beta Standard Error  Sig  
      
 Depression  -8.72 0.81 ***  
 No Depression (Reference 
Group)    
 
      
Fully-Adjusted Model:  Parameter Estimates and Standard Errors for Depression  
Ordinary Least Squares Regression  
Physical Component Summary Score  
  Beta Standard Error Sig  
 Depression  -1.29 0.81   
 No Depression (Reference 
Group)    
 
      
 
Note: Based on 2,662 adults with Rheumatoid Arthritis aged between 18 and 64 years, who were alive during the 
calendar year.    Asterisks represent significant group differences by the presence of depression.  The ordinary least 
squares regressions controlled for the following variables:  sex, race/ethnicity, age, region, marital status, education, 
family poverty status, health insurance, anxiety, multimorbidity, obesity, physical activity and smoking. 
 
SE:  Standard error; Wt.:  Weighted  
 
*** p < .001; ** .001 ≤ p < .01; * .01 ≤ p < .05.  
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Table 2.4. Economic Outcomes by Presence of Depression 
among Working Age Adults with Rheumatoid Arthritis 
Medical Expenditure Panel Survey (2009, 2011, 2013 and 2015)  
 RA + Depression   RA and No Depression  
 
 
 Wt. Mean SE Wt. Mean SE Sig 
All             N =647                N =2,015                 
Total Healthcare Expenditures 
(2015 $)  
17,941 1489 10,064 574 *** 
Total Out-of-Pocket Spending by 
Patients/Families (2015 $)  
$1,443 135 $1,052 73 *** 
      
Adjusted Total Direct Healthcare Expenditures of Depression  
from Generalized Linear Models with Gamma Distribution and Log link    
 RA + Depression RA and No Depression  
 Wt. Mean 95% CI Wt. Mean 95% CI Sig 
     *** 
Total Healthcare Expenditures 
(2015 $) 
14,752 (14,411 – 
 15,125) 
10,541 (10,206-
10,806) 
 
Total Out-of-Pocket Spending by 
Patients/Families (2015 $) 
1,232 (1,202-1265) 979 (955 – 
1,005)  
*** 
      
Incremental Total Direct Healthcare Expenditures of Depression  
from Counterfactual Recycled Prediction   
 Wt. Mean 95% CI    
Total Healthcare Expenditures 
(2015 $) 
4,212 (4,114, 4318)   *** 
Total Out-of-Pocket Spending by 
Patients/their families (2015 $) 
253 (247-260)   *** 
      
High Out-of-pocket Spending Burden (> 10% Income Spent on Healthcare)   
 RA + Depression   RA and No Depression  
 
 N Wt. Col % N Wt. Col % Sig 
High Out-of-pocket Spending 
Burden 
192 30.7 424 21.3 *** 
      
Fully-Adjusted Model:  Adjusted Odds Ratio (AOR) and 95% Confidence Intervals (CI) of Depression  
 from Logistic Regression on High Out-of-Pocket Burden 
 AOR 95% CI Sig   
Depression  1.34 [1.01, 1.79]  **   
No Depression (Reference)      
      
Unemployment among Working-Age Adults    
 RA + Depression   RA and No Depression  
 
  N Wt. col % N Wt. Col % Sig 
Unemployed  452 64.1 900 40.1 *** 
      
Fully-Adjusted Model:  Adjusted Odds Ratio (AOR) and 95% Confidence Intervals (CI) of Depression 
 from Logistic Regression on Unemployment  
 AOR 95% CI Sig   
Depression  1.55 [1.14, 2.10] ***   
No Depression (Reference)      
      
(Continued)      
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Table 2.4. Economic Outcomes by Presence of Depression 
among Working Age Adults with Rheumatoid Arthritis 
Medical Expenditure Panel Survey (2009, 2011, 2013 and 2015) 
Fully-Adjusted Models: Total Productivity Losses by Depression from 
from Negative Binomial Regression on Missed Work Days  
  RA + Depression   RA and No Depression   
 Wt. Mean 95% CI Wt. Mean 95% CI Sig 
     *** 
Number of Missed Work Days  9.0 (8.7 – 9.4) 6.0 (5.7 – 6.2)  
Lost Wages  853 (833-873) 571 (558-584) *** 
      
Incremental Total Productivity Losses Associated with Depression  
from Counterfactual Recycled Prediction   
      
 Wt. Mean 95% CI    
Number of Missed Work Days  3.1 (2.9 – 3.2)   * 
Lost Wages  282 (276- 289   * 
      
 
Note: Based on 2,662 adults with Rheumatoid Arthritis aged between 18 and 64 years, who were alive during the 
calendar year.    Asterisks represent significant group differences by the presence of depression.  The adjusted 
models controlled for the following variables:  sex, race/ethnicity, age, region, marital status, education, family 
poverty status, health insurance, physical health, mental health status, anxiety, multimorbidity, obesity, physical 
activity and smoking. 
 
Missed work days and lost wages were estimated only for those who were employed.  
 
*** p < .001; ** .001 ≤ p < .01; * .01 ≤ p < .05.  
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CHAPTER 3 
3 Depression and Treatment Response to Tumor Necrosis Factor Inhibitor Therapy 
among Working-Age Adults with Rheumatoid Arthritis: A Post Regression Non-Linear 
Decomposition Approach 
3.1 Abstract 
Objective. We examined the relationship between prevalent depression and treatment response to 
Tumor Necrosis Factor Inhibitor(TNFi) therapy among working-age adults with Rheumatoid 
Arthritis(RA).  Method. We adopted a retrospective cohort study design with data from a 
commercially-insured population using QuintilesIMS RWD Adjudicated Claims for the period 
October 1, 2009 to September 30, 2015. The study population (N = 6,970) comprised working-
age (18-63 years) adults with RA, who were initiated on TNFi therapy. Response to TNFi 
therapy during the 1-year follow-up period was measured using a validated claims-based 
algorithm. Logistic regression was used to examine the association between depression and 
treatment response to TNFi after adjusting for patient characteristics. A post-regression 
decomposition method was used to quantify how much of the difference in rates of treatment 
response reflected the explained and unexplained factors. Results. Overall, 12.5% of RA patients 
had depression. A significantly higher proportion of RA patients without depression responded 
to TNFi-therapy as compared to RA patients with depression (39.4% vs. 31.5%). After adjusting 
for baseline risk factors, adults with depression were 22% less likely to respond to TNFi therapy 
(AOR=0.78, 95% CI: 0.66, 0.92). Decomposition analysis revealed that 36.7% of the difference 
in treatment response between the “depression” and “no depression group” were due to observed 
differences in patient characteristics such as the presence of anxiety, glucocorticoid use, and 
opioid use. Conclusion. These findings highlight the negative impact of depression on treatment 
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response to TNFi and provide insights into specific subgroups of RA patients with depression 
who are at risk of responding poorly to TNFi. 
3.2 Introduction  
Tumor Necrosis Factor Inhibitors (TNFi) are the most widely used first-line biologic 
therapies in Rheumatoid Arthritis (RA) patients with moderate-to-severe disease who fail 
treatment with conventional DMARDS such as methotrexate, sulfasalazine and 
hydroxychloroquine 57. Although TNFi therapy has proven to be highly efficacious in controlling 
disease activity in moderate-to-severe RA; there is considerable heterogeneity in treatment 
response to TNFi. In routine clinical practice, only one-third of RA patients respond to TNFi 102. 
The variability in treatment response to TNFi may be associated with the presence of co-existing 
chronic conditions 103. Depression is one of the highly prevalent chronic condition in RA patients 
15 and may affect RA through shared biologic pathways 100,104. Depression is now increasingly 
viewed as an inflammatory condition that is caused by an overactive immune system and may 
exert a negative influence on treatment response in RA by its effect on pro-inflammatory 
cytokines 12,105. Therefore, it is important to understand the relation between depression and 
particular anti-cytokine therapies in RA such as TNFi. 
Previous studies have shown a strong association between depression and disease activity 
in RA 28,106,107. In a randomized controlled trial, researchers found that RA patients with baseline 
depression were more likely to have higher RA disease activity and physical disability as 
compared to those without depression28. This study also demonstrated those with depression 
were 50% less likely to respond to glucocorticoid treatment in RA compared to those without 
depression 28. In another study of 59 RA patients treated in a Rheumatology Clinic in United 
Kingdom, RA patients with persistent depressive symptoms were found to have lower reductions 
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in RA disease activity as compared to those without depression 32. However, this was a 
descriptive study and the small sample size did not allow to adjust for other potential risk factors 
such as the demographics and the clinical characteristics of the patients. Another study done 
using the United States’ RA registry data reported that the presence of depressive symptoms was 
associated with a reduced likelihood of clinical remission at 6 months but did not affect clinical 
remission significantly at 12 months 29. However, this study assessed depression as one of the 
independent variables within a multivariate framework and did not evaluate the extent to which 
each of the individual patient level characteristics such as demographics and clinical factors, 
contributes to the difference in treatment response to TNFi by depression status.  
The current study extends the literature by using post-regression non-linear 
decomposition technique to explain patient characteristics that may contribute to poor treatment 
response to TNFi among RA patients with depression. Such analysis can inform patients, payers 
and providers to identify patient subgroups that are at risk of responding poorly to TNFi and 
therefore target these patients for closer monitoring.  
Therefore, the primary objective of this study was to examine the effect of coexisting 
depression on treatment response to TNFi therapy among working-age RA patients and examine 
the extent to which differences in individual patient characteristics explain the observed 
difference in treatment response between RA patients with depression and those without 
depression by using post-regression non-linear decomposition technique.  We focused on 
working-age adults because the prevalence of depression is particularly high among working-age 
RA patients 15,51. Lack of treatment response due to depression may further add to the disability 
burden and productivity losses among working-age RA patients 108. 
Conceptual Framework 
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The conceptual framework for this study is adapted from the Andersen’s Expanded 
Behavioral Model69 which posits that the healthcare utilization by an individual is a function of 
predisposing factors (e.g. age, sex ), enabling factors (e.g. insurance plan type, calendar year of 
TNFi initiation), need factors (e.g. number of chronic physical conditions, anxiety, substance 
abuse, any emergency room visit, any inpatient visit, RA-related medication use) and external 
environment factors (e.g. geographical region). As the treatment response to TNFi was 
operationalized based on prescription drug utilization, Andersen’s Behavioral Model was an 
appropriate conceptual model for selecting the independent variables in our study. The 
predisposing factors represent the individual characteristics that predict the propensity for the use 
of healthcare services. The enabling factors represent the factors that enable an individual to gain 
access to healthcare services. The need factors are those characteristics that define an 
individual’s health status. The external environment represents the environmental and 
geographical factors that influence an individual’s health service utilization. 
3.3 Methods 
Study Design 
A retrospective observational cohort study design with baseline and follow-up period was 
used. The first observed prescription date for a TNFi biologic (adalimumab, infliximab, 
etanercept, golimumab and certolizumab pegol) between October 2010 and September 2014 was 
used as the index date. Using this index date, the study period was divided into 12 months pre-
index (i.e. baseline period) and 12 months post-index (i.e. follow up period). 
Data 
We used data from QuintilesIMS Real World Data Adjudicated Claims for the period 
October 1, 2009 to September 30, 2015. This is an integrated claims database that includes 
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enrollment, medical and pharmacy claims information for more than 95 million enrollees of 
commercial plans across the US. The data includes the records of 90% of hospitals, 80% of 
doctors and 85% of large companies in the US. This database also records enrollees 
demographics (year of birth, gender, geographic region), plan type (health maintenance 
organization, preferred provider organization), payer type (commercial, self-insured), 
prescription drug information and considered nationally representative of commercially insured 
individuals less than 65 years of age in the US. 
Study Population  
The study population included adults aged between 18 and 63 years at the index date, 
with a diagnosis of RA (ICD-9-CM: 714.0x) in the baseline period and initiated on TNFi therapy 
between October 2010 and September 2014 (Supplemental Figure 7.1.1). Continuous enrollment 
in both pharmacy and medical benefits was required for the 12 months baseline period and 12 
months follow up period. Adults with any biologic use during the baseline period were excluded. 
In addition, adults diagnosed with other autoimmune conditions for which biologics are used 
(Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriasis, psoriatic arthritis, juvenile 
idiopathic arthritis) during the baseline or treatment or follow-up period were excluded. 
Furthermore, adults diagnosed with Non-Hodgkin’s lymphoma, chronic lymphocytic leukemia 
or HIV/AIDS were also excluded.   
Measures 
Dependent variable: Response to Treatment with TNFi (Yes/No) 
Treatment response in RA is typically measured using Disease Activity Soring in 28 
joints (DAS-28) and is considered a gold standard approach to measuring treatment response.  
However, DAS-28 are not available in claims data.  Therefore, Curtis et.al developed a claims-
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based algorithm for measuring the treatment response to biologics in RA by using variables that 
are readily available in claims data such as medication use, adherence, switching, and dose 
escalation 109. This algorithm was initially developed by using the Veteran Health Administration 
(VHA) claims database linked with VHA registry data and validated by using DAS-28 scores 
from the laboratory results from the VHA registry data. A high positive predictive value of 87% 
was found when the performance of this algorithm was tested using commercial claims data and 
change in DAS28110.  
Claims-based Algorithm Components:  
As per the algorithm, RA patients initiating TNFi therapy were considered to have an 
effective response to TNFi therapy if they statisfied all of the following 6 criteria: 
(1) Adherence to index TNFi: Adherence to TNFi was calculated using proportion of 
days covered (PDC). The PDC was calculated by using the date of service and the days of supply 
for each fill of the index TNFi. Patients with a PDC of at least 80% were considered adherent. 
Patients taking infliximab, were considered adherent if they had at least 7 infusions in the 1-year 
treatment period.  
 (2) No increase in TNFi dose compared to the first dose:  Dose increases were measured 
based on the type of TNFi medications.  For Adalimumab (subcutaneous) users, the dose 
escalation criteria required no more than 40 mg per week; for Certolizumab pegol 
(subcutaneous) users the dose escalation criteria was ≥200 mg (after 56 days) of the index-dose; 
for Etanercept (subcutaneous) users, the dose escalation criteria was ≥100 mg/week of the index 
dose; for Golimumab (intravenous) users, the dose escalation criteria was ≥50 mg from the first 
to the last dose; for Golimumab (subcutaneous) users the dose escalation criteria was ≥25 
mg/week post-index (i.e., >50 mg monthly post-index); for Infliximab users, the dose escalation 
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criteria were ≥100 mg from the first to last dose or <11 infusions during the 1 year post-index 
period or ≥7 weeks between doses (after the third dose). 
(3) No new conventional synthetic DMARD: No addition of methotrexate, sulfasalazine, 
leflunomide, or hydroxychloroquine in the treatment period in RA patients who did not have any 
claims for that drug in the baseline period. 
(4) No switch to another biologic drug approved for use in patients with RA.  
(5) No new/increased oral glucocorticoid: Patients with no claims for oral 
glucocorticoids in the baseline period: could not receive more than 30 days of oral 
glucocorticoids between the (index date + 91days) to (index date + 365days); for patients with 
claims of oral glucocorticoids, there should have been no increase in the oral glucocorticoid dose 
from the 6th to the 12th month after the index date compared to the 6 months before the index 
date. Escalation in oral glucocorticoid dose was determined based on prednisone equivalent dose 
for all glucocorticoids. 
(6) At most one parenteral or intra-articular glucocorticoid joint injection on unique days 
in months 4 to 12 of the post-index period. 
Using the above-mentioned components, we classified treatment response to TNFi as a 
dichotomous variable (Yes/No) during a one-year treatment period (one-year after the index 
date). 
Key Independent Variable: Prevalent Depression  
Depression in the baseline period was identified using a standard algorithm 111,112. Adults 
with ICD-9-CM codes of 296.2 (major depressive disorder, single episode), 296.3 (major 
depressive disorder, recurrent episode), 298.0 (depressive type psychosis), 300.4 (neurotic 
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depression), 309.1 (prolonged depressive reaction), and 311 (depressive disorder, not classified) 
during the baseline period were considered to have co-existing depression.   
Other independent variables:  
Other independent variables measured during the baseline period included predisposing 
characteristics - age, sex, enabling characteristics insurance plan type(health maintenance 
organizations [HMOs]; preferred provider organizations [PPOs]), need characteristics included 
the total number of chronic physical conditions, anxiety and substance abuse, healthcare 
utilization (any inpatient and any emergency room visit), and RA related medication use 
(methotrexate, other DMARDs, glucocorticoids, NSAIDs and opioids).  The total number of 
chronic physical conditions was measured using the Clinical Classifications Software managed 
by the Agency for Healthcare Research and Quality (AHRQ).  The external environment 
characteristics included the index year of TNFi initiation and geographic region (East, Midwest, 
South, and West).  
Statistical Analysis 
We used chi-square tests to examine the unadjusted differences in treatment response by 
the presence of depression. To examine the association between depression and treatment 
response to TNFi after adjusting for the pre-disposing, enabling, need and external environment 
factors, adjusted logistic regressions were conducted separately for RA patients with depression 
and RA patients without depression and the two groups combined (RA patients with and without 
depression). A post-regression non-linear decomposition technique was used to examine the 
extent to which individual patient characteristics explained the difference in treatment response 
between the group with depression and the group without depression.  
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Previous research has often used a binary indicator variable for depression within a 
multivariate framework and did not examine how much of the observed difference in treatment 
response can be explained by differences in characteristics between the depression and no 
depression group. The decomposition method aids in identifying which patient-level factors 
accounted for how much of the difference in the treatment response between the group with 
depression and the group without depression. The decomposition technique is a sophisticated 
econometric method that quantifies how much of the difference in rates reflects the observable or 
explained factors (e.g. sex, age, medications) versus unobservable or unexplained factors (e.g. 
physiologic difference, lifestyle difference, education, income).  In this study, as the dependent 
variable was binary (depression vs. no depression), we used the nonlinear decomposition 
technique proposed by Fairlie 113 and modified by Yun 114.  We conducted logistic regression 
analyses using Statistical Analysis Software (SAS) version 9.3, Cary, NC, USA and 
decomposition with STATA 14. 
3.4 Results  
Table 3.1 presents the characteristics of the study population by the presence of 
depression in the baseline period. Of the 6,970 working-age patients with RA, initiated on TNFi 
therapy, an overwhelming majority were female (75.9%) and the mean age was 50 years. 
Overall, 12.5% of the study population had co-existing depression during the baseline period. 
More than one-third of the study population had at least one additional chronic physical 
condition. 
There were statistically significant differences in the baseline characteristics of those with 
depression versus those without depression with respect to sex, the number of chronic physical 
conditions, any emergency room visit, any inpatient visit, substance abuse, anxiety and RA 
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related medication use (Table 3.1). For example, a significantly higher proportion of RA patients 
with depression were female (88.2% vs. 74.2%), had comorbid anxiety (28% vs. 6%), had 1 to 3 
additional chronic physical conditions (41.6% vs. 32.6%), had an emergency room visit during 
the baseline period (36.9% vs. 21.6%), and had RA-related medication use compared to those 
without depression.   
Response to TNFi treatment by Depression: 
Based on the algorithm, 39.8% (N=2,676) of the study population responded to TNFi 
therapy during the one-year follow-up period (Table 3.2). The most common reason for non-
response to TNFi therapy was low adherence to index TNFi (43.1%). A significantly lower 
proportion of RA patients with co-existing depression responded to treatment with TNFi therapy 
as compared to RA patients without co-existing depression (31.5% vs. 39.4%; p < .001) (Table 
3.2).  
The top panel of Table 3.3 displays results from the pooled logistic regression of 
treatment response to TNFi. In this regression, RA patients with depression and without 
depression were combined and the difference in treatment response between those with 
depression vs. those without depression was measured using an indicator variable for depression 
(with no depression as the reference group), after adjusting for the explanatory variables. After 
adjusting for baseline risk factors, those with depression were 22% less likely to respond to TNFi 
therapy compared to those without depression (AOR=0.78, 95% CI: 0.66, 0.92). 
Table 3 also presents AORs and 95% CIs from the logistic regression on treatment 
response to TNFi conducted separately for RA patients with depression and without depression.  
We observed differences in associations between the independent variables and treatment 
response by the depression status.  For example, among those without depression, females were 
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significantly less likely to respond to TNFi treatment as compared to males (AOR = 0.88; 95% 
CI = 0.78, 0.99); there was no sex difference in treatment response among adults with 
depression.  Among RA patients without depression, those who had anxiety were significantly 
less likely to respond to TNFi treatment, whereas among RA patients with depression there were 
no differences in treatment response by presence of anxiety. 
The results from the decomposition of the differences between RA patients with 
depression vs. RA patients without depression in treatment response to TNFi is shown in Table 
3.4.  Overall, there was a 7.9 percentage point difference in treatment response to TNFi between 
RA patients with depression vs. RA patients without depression (p<0.001).   The differences in 
observed characteristics between RA patients with depression and those without depression 
explained only 37.1% (i.e. 2.9 percentage points out of the 7.9 percentage point difference). This 
implies that the difference in treatment response to TNFi between those with depression versus 
those without depression would be reduced by 37.1% if those with depression had a similar 
distribution of baseline characteristics as those without depression.  
Table 3.4 also summarized the individual contribution of factors to the disparity in 
treatment response rate between depression and no depression group.  A positive sign represents 
a reduction in the disparity in treatment response between depression and no depression group 
and a negative sign represents an increase in disparity in treatment response between the 
depression and no depression group. Presence of anxiety in the baseline was a major contributor 
to the total difference in treatment response to TNFi and accounted for 19.2% of the explained 
portion in treatment response. If all baseline characteristics remained the same and if the 
prevalence pattern for anxiety was the same between RA patients with and without anxiety, the 
difference in treatment response would drop by 1.5 percentage points to 6.4 percentage points.  
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The use of RA-related medications followed different patterns.  For example, 
glucocorticoids and opioid pain medication explained 17.9% of the total difference in treatment 
response rate. If RA patients with depression had the same rate of glucocorticoids and opioid 
pain medication use, then the difference in treatment response between depression and no 
depression group would be reduced by 1.4 percentage points (i.e. from 7.9% to 6.5%).  However, 
if RA patients with depression had the same rates of NSAIDs, methotrexate, and other 
DMARDs, then the gap in treatment response rate between the depression and no depression will 
actually increase by 0.74 percentage points (i.e. from 7.9% to 8.64).  
3.5 Discussion  
In this study, we used large administrative claims data to examine the rate of treatment 
response to TNFi for RA patients with depression in comparison to RA patients without 
depression and quantified how much of the difference in treatment response rates between the 
two groups reflected differences in observable characteristics between the two groups. We found 
that working-age adults with RA and depression were less likely to respond to treatment 
compared to those without depression. A plausible explanation is that depression may affect 
treatment response to anti-rheumatic therapies through dysregulation of inflammatory 
pathways115. This is consistent with studies that have documented the negative effect of 
depression on disease activity and clinical remission in RA 28,29,106,107.  It is also possible that 
adults with depression may not adhere to therapies, which may affect treatment response. Many 
studies have documented the negative effects of depression on treatment adherence in RA 
patients 48,116. In our study, we observed that a significantly higher percentage of RA patients 
with depression had low adherence to TNFi compared to those without depression (49.8% vs 
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42.2%).  Such non-adherence to treatments associated with depression may further heighten the 
disability burden and productivity loss among working-age RA patients (Li, Gignac et al. 2006). 
Our findings also underscore the need for co-managing RA and depression. There is 
preliminary evidence that depression treatment can improve treatment response in patients with 
arthritis.  Emerging research suggests that antidepressants used for treating depression can 
improve RA treatment efficacy117.  A recent case report suggested that specific Serotonin 
reuptake inhibitor antidepressant drugs, often used to treat depression, may improve clinical 
outcomes in RA patients 118.  Furthermore, the anti-inflammatory properties of antidepressants 
may help alleviate pain and fatigue in rheumatoid arthritis119.  If more studies confirm the 
association between depression treatment and treatment response to TNFi therapy, then 
depression treatment needs to be integrated into RA care to improve clinical outcomes.   
Results from the post-regression decomposition analyses revealed that differences in 
anxiety prevalence explained a substantial portion of the observed difference in treatment 
response to TNFi. It is well-documented that anxiety disorders are common in patients with 
major depression 120,121. Co-occurring anxiety and depression in RA patients may with associated 
with higher symptom severity and disease activity leading to sub-optimal treatment response 122. 
Therefore, our findings suggest that RA patients with co-existing anxiety and depression should 
be monitored more closely and should be treated with effective pharmacological and behavioral 
therapies to improve treatment response in RA.  
In addition to anxiety, differences in baseline RA-related medication use among RA 
patients with depression and no depression also contributed to the observed difference in 
treatment response to TNFi. For example, RA patients with depression were more likely to use 
glucocorticoids and opioid pain medications as compared to RA patients without depression. Our 
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findings suggest that reducing the rate of glucocorticoid and opioid medication use in RA 
patients with depression would significantly reduce the gap in treatment response to TNFi. This 
is because the long-term use of both glucocorticoids and opioid medications have been 
associated with increased risk of depression123,124.    
We also found that only 37.1% of the differences in response rate between depression 
and no depression group can be explained by observed differences in patient characteristics. The 
explained portion could have been low because our study did not include life-style risk factors, 
the severity of illness, and other physiologic that may explain treatment response.   
The findings of this study need to be interpreted in the context of its limitations and 
strengths. The strengths include a large commercially insured population that is nationally 
representative of working-age adults, ability to measure treatment effectiveness, use of 
decomposition methods, and measurement of concomitant medications.  Potential limitations of 
the study include the lack of severity measures for RA and depression.  However, by including 
only those who were initiated on TNFi, we ensured that the patients in our study had moderate or 
severe RA.  Similarly, by using major depressive disorder, we included only those with clinically 
significant depression.  It is possible that depression was underdiagnosed and the “no 
depression” group included those with depression as well. This may have underestimated the 
differences in treatment response.  We did not have information on individual characteristics 
such as race, body mass index, exercise and smoking status that may affect treatment response 
and underestimate the contribution of explanatory variables to the disparity in treatment response 
between the depression and no depression group.  In claims data, we can only observe filled 
prescriptions of medications and not actual use of medication.  Although we used a “wash out” 
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period to identify TNFi initiators, we cannot assert they are truly naïve to TNF inhibitors because 
they may have used it before the washout period (i.e. 12 months). 
3.6 Conclusion 
Notwithstanding the limitations, our study provides important insights on the negative 
effect of comorbid depression on treatment response to TNFi from a population-based 
perspective. Future studies need to assess whether increasing diagnosis and treatment of 
depression in RA patients may improve treatment response and clinical outcome associated with 
particular anti-rheumatic therapies. 
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Table 3.1. Description of Working-age Adults with Rheumatoid Arthritis initiated on TNFi 
by Depression Status During Baseline  
QuintilesIMS Real-World Data Adjudicated Claims Database, 2009 – 2015 
  Total Depression No Depression  
    N %  N  %  N  % Sig 
All 6,970 100.0    868  100     6,102  100  
Predisposing Characteristics 
Sex        *** 
 Female       5,293  75.9          766  88.2       4,527  74.2  
 Male          1,677  24.1              102  11.8 1,575  25.8  
Age        
 18-34 years           612  8.8                90  10.4        522  8.6  
 35-44 years          1,155  16.6              154  17.7    1,001  16.4  
 45-54 years           2,500  35.9              311  35.8      2,189  35.9  
 55-63 years           2,703  38.8              313  36.1       2,390  39.2  
Enabling Characteristics 
Insurance Plan Type         
 HMO              691  9.9                88  10.1          603  9.9  
 PPO           5,416  77.7              664  76.5       4,752  77.9  
 Other              863  12.4              116  13.4          747  12.2  
Need Characteristics 
Number of Chronic Physical Conditions     *** 
 0           4,428  63.5 467 53.8       3,961  64.9  
 1 to 3       2,351  33.7 361 41.6     1,990  32.6  
 >3              191  2.7 40 4.6      151  2.5  
Substance Abuse       *** 
 Yes           1,638  23.5                86  9.9        373  6.1  
 No           5,332  76.5              782  90.1      5,729  93.9  
Anxiety       *** 
 Yes        614  8.8              243  28.0        365  6.0  
 No     6,356  91.2              625  72.0     5,737  94.0  
Health Services Utilization  
ED Visits        *** 
 Yes        459  6.6 320 36.9     1,318  21.6  
 No   6,511  93.4 548 63.1      4,784  78.4  
IP Visits        *** 
 Yes         608  8.7 149 17.2         465  7.6  
 No     6,362  91.3 719 82.8     5,637  92.4  
Healthcare Utilization – Medication Use 
NSAIDS       ** 
 Yes        3,883  55.7              524  60.4       3,359  55  
 No         3,087  44.3              344  39.6      2,743  45  
Methotrexate       * 
 Yes           5,080  72.9              659  75.9       4,421  72.5  
 No          1,890  27.1              209  24.1 1,681  27.5  
         
Other DMARDS†      *** 
 Yes     3,491  50.1              492  56.7     2,999  49.1  
 No          3,479  49.9              376  43.3 3,103  50.9  
Glucocorticoids       ** 
 Yes         5,025  72.1         663  76.4       4,362  71.5  
 No       1,945  27.9          205  23.6      1,740  28.5  
         
         
(Continued)        
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Table 3.1. Description of Working-age Adults with Rheumatoid Arthritis initiated on TNFi 
by Depression Status During Baseline  
QuintilesIMS Real-World Data Adjudicated Claims Database, 2009 – 2015 
  Total Depression No Depression  
    N %  N  %  N  % Sig 
Opioids       *** 
 Yes          3,912  56.1 638  73.5 3,274  53.7  
 No        3,058  43.9  230  26.5  2,828  46.3  
External Environment Characteristics 
Index Year        
 2010             401  5.8                46  5.3        355  5.8  
 2011          1,813  26.0              221  25.5       1,592  26.1  
 2012          1,878  26.9              262  30.2       1,616  26.5  
 2013           1,713  24.6              218  25.1       1,495  24.5  
 2014           1,165  16.7              121  13.9       1,044  17.1  
Region        
 East         1,213  17.4          152  17.5     1,061  17.4  
 Midwest          2,083  29.9         275  31.7     1,808  29.6  
 South          3,077  44.1          348  40.1     2,729  44.7  
 West             597  8.6                93  10.7         504  8.3  
         
 
Note: Based on 6,970adults with Rheumatoid arthritis aged between 18 and 63 as of the index date, initiated on Tumor 
Necrosis Factor Inhibitors between 2010 and 2014, with continuous enrollment for 12 months baseline and 12 months 
follow-up periods in a commercial insurance plan.  
 
Asterisks represent significant group differences by the presence of depression based on chi-square tests.  
 
† include Sulfasalazine, Leflunomide, Hydroxychloroquine, Azathioprine, Chloroquine, Cyclophosphamide, 
Cyclosporine, Minocycline, and Sodium Aurothiomalate.  
 
DMARDS: Disease modifying anti-rheumatic drugs; ED: Emergency department; HMO: Health maintenance 
organization; PPO: Preferred provider organization; IP: Inpatient; NSAIDS: Nonsteroidal anti-inflammatory drugs. 
*** p < .001;  ** .001 ≤ p < .01; * .01 ≤ p < .05 
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Table 3.2. Components of the Algorithm for TNFi Response Status at 1 year after TNFi Initiation 
Working-age Adults with Rheumatoid Arthritis initiated on TNFi  
By Depression Status  
QuintilesIMS Real-World Data Adjudicated Claims Database, 2009 – 2015 
 ALL Depression 
No 
Depression  
Sig 
Low adherence to index TNFi 
(PDC<0.8) 43.1% 49.8% 42.2% 
 
*** 
Switched to new biologics 23.5% 27.4% 22.9% *** 
Dose escalation of TNFi 8.9% 10.6% 8.6% *** 
Conventional DMARD addition after 
index 3.3% 2.1% 3.4% 
*** 
Dose increase of oral glucocorticoid 15.8% 19.7% 15.2% *** 
> 1 glucocorticoid joint injection 2.6% 4.6% 2.3% *** 
     
Responded to TNFi Therapy 38.4% 31.5% 39.4% *** 
Not Responded to TNFi Therapy  61.6% 68.5% 60.6%  
     
 
Note: Based on 6,970 adults with Rheumatoid Arthritis aged between 18 and 63 as of the index date, initiated on Tumor 
Necrosis Factor Inhibitors between 2010 and 2014, with continuous enrollment for 12 months baseline and 12 months 
follow-up periods in a commercial insurance plan.  
 
Asterisks represent significant group differences by the presence of depression based on chi-square tests.  
 
Individual components of TNFi response criteria will not add to 38.4% because an individual may satisfy one or 
more components of the TNFI response algorithm. 
 
PDC:  Proportion of days covered; TNFi:  Tumor Necrosis Factor Inhibitor 
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Table 3.3. Adjusted Odds Ratios (AOR) and 95% Confidence intervals (CI)  
from Separate Logistic Regressions on Response to TNFi by Depression Status  
Working-age Adults with Rheumatoid Arthritis Initiated on TNFi  
QuintilesIMS Real-World Data Adjudicated Claims Database, 2009 – 2015 
    Depression No Depression Pooled Regression 
    AOR  95% CI Sig AOR  95% CI Sig AOR  95% CI Sig 
Depression          
 Yes       0.78 [0.66,0.92] ** 
  No             Ref     
Predisposing Characteristics 
Sex          
 Female 1.01 [0.64,1.60]  0.88 [0.78,0.99] * 0.88 [0.79,0.99] * 
 Male Ref      Ref   
Age          
 18-34 years Ref   Ref   Ref   
 35-44 years 1.21 [0.65,2.23]  1.09 [0.87,1.36]  1.10 [0.89,1.36]  
 45-54 years 1.39 [0.79,2.43]  1.25 [1.02,1.54] * 1.27 [1.05,1.54] * 
 55-63 years 1.89 [1.07,3.34] * 1.32 [1.07,1.63] ** 1.38 [1.14,1.68] ** 
Enabling Characteristics 
Insurance Plan Type          
 HMO Ref   Ref   Ref   
 PPO 1.41 [0.82,2.43]  1.01 [0.84,1.22]  1.03 [0.87,1.23]  
 Other 1.95 [1.03,3.70] * 1.25 [1.00,1.56]  1.30 [1.05,1.60] * 
Need Characteristics  
Number of Chronic Physical Conditions        
 0 Ref   Ref   Ref   
 1 to 3 0.89 [0.65,1.23]  1.06 [0.94,1.19]  1.04 [0.93,1.16]  
 >3 0.56 [0.25,1.27]  0.91 [0.63,1.30]  0.85 [0.61,1.18]  
Substance Abuse          
 Yes 1.28 [0.72,2.29]  0.92 [0.71,1.19]  0.96 [0.76,1.21]  
 No Ref   Ref   Ref   
Anxiety          
 Yes 1.10 [0.79,1.55]  0.72 [0.57,0.92] ** 0.83 [0.69,1.01]  
 No Ref   Ref   Ref   
Health Services Utilization 
ED Visit          
 Yes 0.70 [0.50,0.99] * 0.88 [0.76,1.01]  0.85 [0.75,0.96] * 
 No Ref   Ref   Ref   
IP Visit          
 Yes 1.21 [0.79,1.87]  1.06 [0.86,1.32]  1.09 [0.90,1.32]  
 No Ref   Ref   Ref   
Health Services Utilization – Medication Use  
NSAIDS          
 Yes 0.97 [0.71,1.32]  1.15 [1.03,1.28] * 1.13 [1.02,1.25] * 
 No Ref   Ref   Ref   
(Continued)          
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Table 3.3. Adjusted Odds Ratios (AOR) and 95% Confidence intervals (CI)  
from Separate Logistic Regressions on Response to TNFi by Depression Status  
Working-age Adults with Rheumatoid Arthritis Initiated on TNFi  
QuintilesIMS Real-World Data Adjudicated Claims Database, 2009 – 2015 
    Depression No Depression Pooled Regression 
    AOR  95% CI Sig AOR  95% CI Sig AOR  95% CI Sig 
Methotrexate          
 Yes 1.31 [0.91,1.88]  1.45 [1.28,1.64] *** 1.43 [1.28,1.61] *** 
 No Ref   Ref   Ref   
Other DMARDS†          
 Yes 0.92 [0.68,1.24]  1.17 [1.05,1.30] ** 1.14 [1.03,1.26] * 
 No Ref   Ref   Ref   
Glucocorticoids          
 Yes 0.62 [0.44,0.88] ** 0.67 [0.60,0.76] *** 0.67 [0.60,0.75] *** 
 No Ref   Ref   Ref   
Opioids          
 Yes 0.96 [0.68,1.35]  0.81 [0.72,0.90] *** 0.82 [0.74,0.91] *** 
 No Ref   Ref   Ref   
External Environment Characteristics  
Region          
 East Ref   Ref   Ref   
 Midwest 1.20 [0.76,1.89]  1.01 [0.86,1.19]  1.03 [0.89,1.20]  
 South 1.17 [0.75,1.84]  0.84 [0.71,0.98] * 0.87 [0.75,1.01]  
 West 1.16 [0.64,2.11]  0.99 [0.79,1.24]  1.01 [0.82,1.25]  
Index Year          
 2010 Ref   Ref   Ref   
 2011 0.95 [0.47,1.92]  0.88 [0.69,1.11]  0.88 [0.71,1.11]  
 2012 0.89 [0.44,1.76]  0.82 [0.65,1.04]  0.83 [0.66,1.03]  
 2013 0.96 [0.48,1.94]  0.89 [0.70,1.13]  0.90 [0.71,1.12]  
 2014 1.02 [0.48,2.15]  0.9 [0.70,1.15]  0.91 [0.72,1.15]  
           
 
Note: Based on 6,970 adults with Rheumatoid Arthritis aged between 18 and 63 as of the index date, initiated on Tumor 
Necrosis Factor Inhibitors between 2010 and 2014, with continuous enrollment for 12 months baseline and 12 months 
follow-up periods in a commercial insurance plan.  
 
Asterisks represent significant group differences compared to the reference group.  
† include Sulfasalazine, Leflunomide, Hydroxychloroquine, Azathioprine, Chloroquine, Cyclophosphamide, 
Cyclosporine, Minocycline, and Sodium Aurothiomalate.  
 
DMARDS: Disease modifying anti-rheumatic drugs; ER: Emergency room; HMO: Health maintenance organization; 
PPO: Preferred provider organization; IP: Inpatient; NSAIDS: Nonsteroidal anti-inflammatory drugs. 
 
*** p < .001; ** .001 ≤ p < .01; * .01 ≤ p < .05.  
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Table 3.4. Contribution of Individual Characteristics to the  
Observed Difference in TNFi Treatment Response Rate by Depression Status  
Working-age Adults with Rheumatoid Arthritis Initiated on TNFi  
QuintilesIMS Real-World Data Adjudicated Claims Database, 2009 – 2015 
Variables Value in Percentage Points Standard 
Errors 
%Total 
[a]   [b] [c] [d] 
Explained by independent variables     
Differences in Predisposing Characteristics 
 Sex 0.41 0.0020 5.23% 
 Age 0.17 0.0004 2.21% 
Differences in Enabling Characteristics 
 Insurance Plan Type -0.05 0.0003 -0.68% 
Differences in Need Characteristics 
 Number of Chronic Physical Conditions -0.07 0.0011 -0.84% 
 Substance Abuse 0.05 0.0008 0.66% 
 Anxiety 1.52 0.0055 19.22% 
Differences in Health Services Utilization  
 Any Emergency Department Visit 0.46 0.0024 5.78% 
 Any Inpatient Visit -0.14 0.0023 -1.73% 
Differences in Medication Use  
 NSAIDS -0.17 0.0007 -2.16% 
 Methotrexate -0.29 0.0005 -3.72% 
 Other DMARDS -0.27 0.0009 -3.43% 
 Glucocorticoids 0.44 0.0007 5.55% 
 Opioids 0.97 0.0026 12.31% 
Differences in External Environment Characteristics 
 Region -0.19 0.0006 -2.36% 
 Index Year 0.08 0.0006 1.07% 
     
Total explained portion 2.93  37.12% 
Unexplained portion 4.97  62.88% 
 Difference in Treatment Response Rate 
between Depression and No Depression 
Group 7.90   100.0% 
    
 
Note: Based on 6,970 adults with Rheumatoid Arthritis aged between 18 and 63 as of the index date, initiated on Tumor 
Necrosis Factor Inhibitors between 2010 and 2014, with continuous enrollment for 12 months baseline and 12 months 
follow-up periods in a commercial insurance plan.  
 
The decomposition is based on pooled weights.  The pooled weights were derived from parameter estimates of the 
logistic regression on treatment response, using pooled data from both depression and no depression groups. 
 
Column [d] gives the percentage of the difference in treatment response by depression explained by differences in 
each independent variable between the two groups 
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CHAPTER 4 
4 Tumor Necrosis Factor Inhibitor Therapy and the Risk of Developing Depression 
among Working Age Adults with Rheumatoid Arthritis 
4.1 Abstract 
Background. Individuals with Rheumatoid Arthritis (RA) have high risk of developing 
depression because of the overall burden of systemic inflammation. Effective treatment with 
anti-inflammatory drugs specifically, tumor necrosis factor inhibitors (TNFi) may therefore 
reduce the risk of developing depression by lowering the inflammatory burden and improving 
health status in RA patients. Objective. Evaluate the association between TNFi therapy and the 
risk of developing depression among working age adults with RA. Method. A retrospective 
observational cohort study design was used with data derived from commercial claims data from 
QuintilesIMS RWD Adjudicated Claims for the period October 1, 2009 to September 30, 2015.  
Working-age adults (18- 62 years) with RA, who were initiated on TNFi therapy and were 
continuously enrolled during the observation periods (one-year baseline, one-year treatment and 
one-year follow-up periods) were included (N=4,222). Treatment response to TNFi was 
measured using prescription drug claims based on published validated algorithm. Multivariable 
logistic regression was used to examine the association between treatment response to TNFi 
therapy and the risk of developing depression, after controlling for baseline demographic 
characteristics, clinical characteristics and RA related medication use. To control for the 
observable differences in the characteristics of the TNFi responders vs. TNFi non-responders, 
inverse probability of treatment weighting technique (IPTW) was used.  Results. Overall, 8.5% 
developed depression during the follow-up period and 39.8% responded to TNFi treatment 
during the one-year treatment period.  A lower percentage of TNFi responders developed 
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depression (7.1% vs. 9.4%, p < .005) as compared to TNFi non-responders. After controlling for 
other risk factors, TNFi responders were 20% less likely to develop depression during the 
follow-up period (AOR = 0.80, 95% CI = 0.64, 0.98) as compared to TNFi non-responders. 
Conclusion. Effective treatment with TNFi therapy reduces the risk of depression in working-age 
adults with RA. 
4.2 Introduction 
Rheumatoid arthritis (RA) is a chronic systemic inflammatory condition that negatively 
impacts both physical and mental health of an individual125,126.  Adults with RA are at higher risk 
of developing depression because of the overall burden of systemic inflammation15,127.  Studies 
have reported increased risk of developing depression after RA diagnosis16. The incident rate of 
depression in RA patients is higher than non-RA patients17. 
The biological plausibility of the link between RA, depression and inflammation stems 
from the robust association between inflammation and depression 63.  It has been reported that 
RA patients with depression have significantly elevated levels of inflammatory biomarkers such 
as TNF-α, c-reactive protein (CRP) as compared to RA patients without depression 12,128-130. 
Human experimental studies have demonstrated that administration of pro-inflammatory 
cytokines in healthy individuals triggers depressive symptoms such as mood disturbances, 
anhedonia, anorexia and sleep disturbance 13,14.    
Risk of depression in RA patients is worrisome because of the negative effects of 
depression on the patient.   For example, depression increases the risk of mortality by more than 
2 folds 73, worsens health related quality of life131, reduces adherence and treatment response to 
anti-rheumatic drugs32,48 and increases healthcare resource utilization and costs47,74. 
 
 
59 
 
Therefore, examining factor that reducing the risk of depression among patients with RA 
is important.  The inflammatory process that affect both depression and RA may represent a 
unique opportunity to reduce the risk of depression in RA patients.  For example, clinical trials 
have provided some evidence on the efficacy of anti-inflammatory agents in reducing depressive 
symptoms 132. In this context, specific drugs used for preventing RA progression may be of 
particular significance. Drugs inhibiting TNF-α (TNFi) have been proven to be highly 
efficacious in reducing inflammation and preventing disease progression in RA56. Due to the 
positive association between depression and inflammation, it is plausible that drugs inhibiting 
TNF-α (TNFi) may reduce the risk of developing depression in RA patients 68. Some randomized 
controlled and open label trials have demonstrated that TNFi therapy improves depressive 
symptoms and quality of life in RA patients 133-135. However, in real world clinical practice only 
one-third of RA patients respond to TNFi therapy 136. Therefore, the beneficial effect of TNFi on 
depression may be limited to RA patients who respond to TNFi therapy. The effect of treatment 
response to TNFi on the risk of developing depression remains unclear from previous studies 133-
135. 
Furthermore, depression in RA has significant implications on working age adults (18-64 
years) because of the illness burden. As the onset of both RA and depression occurs in 
individuals during the most productive mid-life years of lives50,137, the cumulative impact of RA 
and depression on productivity loss due to missed work days, work disability and loss of 
employment among working age adults is concerning 100,138. Therefore, it is important to 
understand pathways that can reduce the risk of developing depression in working-age adults 
with RA. No published studies have specifically evaluated treatment response to TNFi therapy 
on risk of developing depression in this population.  
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Therefore, the objective of this study was to evaluate the treatment response to TNFi on 
the risk of developing depression in working age RA patients who are cared for in real world 
practice setting using administrative claims data. We hypothesize that RA patients who respond 
to TNFi therapy will be significantly less likely to develop depression as compared to RA 
patients who did not respond to TNFi therapy. 
Conceptual Framework: The conceptual framework for this study was adapted from the 
determinants of a health and chronic disease model proposed by Wilkinson and Marmot 70. This 
model delineates the relationship between community resources, access to care variables, 
individual physical make-up, biological risk factors, and treatment factors that affect the 
incidence of chronic conditions. 
4.3 Methods 
Data 
We used data from QuintilesIMS Real World Data Adjudicated Claims for the period 
October 1, 2009 to September 30, 2015. This is an integrated claims database that includes 
enrollment, medical and pharmacy claims information for more than 95 million enrollees of 
commercial plans across the US. The data includes the records of 90% of hospitals, 80% of 
doctors and 85% of large companies in the US. This database also records enrollees 
demographics (year of birth, gender, geographic region), plan type (health maintenance 
organization, preferred provider organization), payer type (commercial, self-insured), 
prescription drug information and considered nationally representative of commercially insured 
individuals less than 65 years of age in the US. 
Study Design 
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A retrospective observational cohort study design was used. The index date was defined 
as the first observed prescription date for a TNFi biologic between October 2010 and September 
2013. The study period was divided into 12 months pre-index or baseline period, 12 months 
treatment period during which the treatment response to TNFi was measured and 1-year follow-
up period when risk of developing depression was assessed.   
Study Cohort – Depression Free RA Patients 
The study cohort consisted of adults aged between 18 and 62 years, with a diagnosis of 
RA in the baseline period and initiated on TNFi therapy between April 2010 and September 
2013 (Supplemental Figure 7.1.2). Continuous enrollment for the 12 months baseline period, 12 
months treatment period and 12 months follow up period was required. Adults with prevalent 
depression during the baseline and treatment period were excluded. In addition, adults diagnosed 
with other autoimmune conditions for which biologics are used (crohn’s disease, ulcerative 
colitis, ankylosing spondylitis, psoriasis, psoriatic arthritis, juvenile idiopathic arthritis) during 
the baseline or treatment or follow-up period were excluded. Furthermore, adults diagnosed with 
Non-Hodgkin’s lymphoma, chronic lymphocytic leukemia or HIV/AIDS were also excluded 
(Supplemental Figure 7.1.2).   
Measures 
Dependent variable:  Newly-diagnosed Depression (Yes/No)  
Depression in the follow-up period was identified using a standard algorithm 111,112. 
Adults with ICD-9-CM codes of 296.2 (major depressive disorder, single episode), 296.3 (major 
depressive disorder, recurrent episode), 298.0 (depressive type psychosis), 300.4 (neurotic 
depression), 309.1 (prolonged depressive reaction), and 311 (depressive disorder, not classified) 
during the follow-up period were considered to have developed depression.   
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Key Independent Variable: Response to Treatment with TNFi (Yes/No)  
Treatment response to TNFi was measured using the claims based effectiveness 
algorithm developed by Curtis et al. 109. Curtis et al. used the Veteran Health Administration 
(VHA) claims database to operationalize treatment response to biologics and validated it using 
the gold-standard for treatment response (i.e. DAS28) from the VHA Rheumatoid Arthritis 
registry109.  The investigators tested the performance of the algorithm in claims database of 
commercially insured individuals110.  A high positive predictive value of 87% was found 
between claims-based algorithim and the gold standard measure of treatment response i.e change 
in DAS28110. Using this algorithm, treatment response to TNFi was measured as a dichotomous 
variable (Yes/No) during a one-year treatment period (one-year after the index date), conditional 
on meeting all the following six criteria: 
(1) Adherence to index TNFi: Adherence to TNFi was calculated using proportion of days 
covered (PDC). The PDC was calculated by using the date of service and the day supply for each 
fill of the index TNFi. Patients with a PDC of at least 80% were considered adherent. Patients 
taking infliximab, were considered adherent if they had at least 7 infusions in the 1-year 
treatment period.  
 (2) No increase in TNFi dose compared to the first dose:  Dose increases were measured based 
on the type of TNFi medications.  For Adalimumab (subcutaneous) users, the dose escalation 
criteria required no more than 40 mg per week; for Certolizumab pegol (subcutaneous) users the 
dose escalation criteria was ≥200 mg (after 56 days) of the index-dose; for Etanercept 
(subcutaneous) users the dose escalation criteria was ≥100 mg/week of the index dose; for 
Golimumab (intravenous) users the dose escalation criteria was ≥50 mg from the first to last 
dose; for Golimumab (subcutaneous) users the dose escalation criteria was ≥25 mg/week post-
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index (i.e., >50 mg monthly post-index); for Infliximab users the dose escalation criteria were 
≥100 mg from the first to last dose or <11 infusion dates post-index or ≥7 weeks between doses 
(after the third dose). 
(3) No new conventional synthetic DMARD: No addition of methotrexate, sulfasalazine, 
leflunomide, or hydroxychloroquine in the treatment period in RA patients who did not have any 
claims for that drug in the baseline period. 
(4) No switch to another biologic drug approved for use in patients with RA.  
(5) No new/increased oral glucocorticoid: For patients with no pre-index oral glucocorticoids, 
<30 days of oral glucocorticoids between the index dates and 90 days post-index; for patients 
with pre-index oral glucocorticoids, a cumulative post-index dose within 120% of the cumulative 
pre-index dose. 
(6) Fewer than 2 glucocorticoid injections (No more than one parenteral or intra-articular 
glucocorticoid joint injection on unique days) in months 4 to 12 of the post-index period. 
Other independent variables:  
Other independent variables measured during the baseline period included the 
demographic characteristics such as age, sex, region(East, Midwest, South, and West), insurance 
and insurance plan type (health maintenance organizations [HMOs]; preferred provider 
organizations (PPOs); clinical characteristics included total number of chronic physical 
conditions, anxiety and substance abuse; healthcare utilization (any inpatient and any ED visit), 
and RA related medication use (glucocorticoids, DMARDs, NSAIDs and opioids). Total number 
of chronic physical conditions was measured using the Clinical Classifications Software 
managed by the Agency for Healthcare Research and Quality (AHRQ). 
Statistical Analysis 
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Chi-square and adjusted odds ratios (AOR) and 95% Confidence intervals (CI) from 
multivariable logistic regression analyses were used to examine the association between 
treatment response to TNF and newly diagnosed depression after controlling for baseline 
demographic characteristics, clinical characteristics and RA related medication use.  As the rate 
of newly diagnosed depression was less than 10%, adjusted odds ratio can be used to 
approximate relative risk 139. Therefore, we used the term risk and odds ratios interchangeably. 
Accounting for observable selection bias: To control for the observable differences in the 
baseline characteristics of the TNFi responders vs. non-responders, inverse probability weighting 
technique (IPTW) was used. This technique gives weight to each individual based on the inverse 
of their probability of being in the responder group. Thus, individuals who have lower 
probability of being in the responder group were up-weighted, and those with higher probability 
of being in the responder group were down weighted. This helped to balance the probability of 
being in the responder group vs the non-responder group. To derive the IPTW weights, logistic 
regression was at first conducted on treatment response to TNFi and probabilities of being in the 
responder vs. non-responder group was calculated, the weights were created using inverse of 
probabilities. To account for the differences in group sizes, the weights were further stabilized by 
dividing them with sample size of each group. All analyses were conducted using SAS 9.4 140 
4.4 Results 
Out of the 4,222 working-age adults with RA who were initiated on TNFi, and were 
depression free during the baseline and treatment period, 75% were female, with a mean age of 
50 years; 45.4% were living in the Southern region of the US; 59% suffered from 1 to 3 
additional chronic condition; 73.5% were on Methotrexate and 55.1% were on NSAIDS during 
the baseline period (Appendix 7.2). 
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Response to TNFi Treatment: 
Based on the algorithm, 39.8% (N=1,679) were classified as responders of TNFi 
treatment during the one-year treatment period after index date (Table 4.1). The most common 
reason for non-response to TNFi therapy was low adherence to index TNFi (42%).  
There were statistically significant differences in the baseline characteristics of the TNFi 
responders and TNFi non-responders in sex, age, insurance, region, insurance plan type and use 
of RA related medications in the baseline (Table 4.2). For example, a significantly higher 
proportion of adults in the TNFi non-responder group used glucocorticoids (75% vs. 67%) and 
opioids (59% vs. 52%). Conversely, the use of Methotrexate in the baseline period was lower in 
the TNFi non-responder group as compared to the TNFi responder group (76% vs. 71%). After 
the application of IPTW, such observable differences were no longer significant as shown in 
Table 4.2. 
Overall, 8.5% developed depression during the follow-up period. A lower percentage of 
TNFi responders developed depression during the one-year follow-up period after treatment as 
compared to TNFi non-responders (7.1% vs. 9.4%; p < .005) After controlling for potential 
confounders, we found that TNFi responders were 20% less likely to develop depression as 
compared to TNFi non-responders with AOR = 0.80 and 95% CI = 0.64,0.98 (Table 4.3).  
Other baseline risk factors for depression included female sex (AOR=2.12; 95% CI=1.64, 
2.74), number of chronic conditions (>3 vs. 0: AOR=1.97; 95% CI=1.34, 2.88), opioid use 
(AOR=2.07; 95% CI=1.69, 2.52) and emergency department visit (AOR=1.32; 95% CI=1.04, 
1.68). 
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4.5 Discussion 
In a depression free cohort of working age RA patients treated with TNFi, we found that 
the overall rate of newly diagnosed depression was 8.5%. In a previous study done in 83 Turkish 
patients with RA treated in an outpatient rheumatology clinic, researchers reported a markedly 
lower prevalence of depressive disorders among patients treated with TNFi (6.3%) as compared 
to those treated with other drugs (41.8%)141. Most epidemiological studies in RA patients have 
examined the prevalence of depression in RA patients15, and only a handful of studies examined 
the incidence of depression in RA patients16,17. A systematic review of 72 studies in RA patients, 
reported a 16.8% prevalence of major depressive disorders 15. In one UK study, approximately 
30% of RA patients developed depression within 5 years of RA diagnosis 16. Therefore, in light 
of these previous findings, the rate of depression in RA patients treated with TNFi appears to be 
lower. In order to determine whether the lower rate of depression is a direct effect of treatment 
with TNFi or whether it could be attributed to improvement in RA disease secondary to 
treatment, future studies need to also incorporate control population of RA patients treated with 
other antirheumatic regimens such as DMARDS.  
A noteworthy finding of our study is that treatment response to TNFi therapy reduced the 
risk of developing depression by 20%, some plausible explanations for this finding is that 
patients who respond to TNFi therapy may have improved RA-related outcomes that may lower 
the risk of developing psychological problems including depression.  TNFi therapy may also 
suppress inflammation and lower the risk of developing subsequent depression12,127.  
The reduction in the risk of depression in TNFi responders has clinical implications for 
treatment of RA as well as depression. Our findings suggest that intervention with TNFi therapy 
may not only improve RA-related outcomes, but also reduce the risk of developing depression.   
Our study findings offer the possibility of including anti-inflammatory agents in treating existing 
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depression and testing whether including anti-inflammatory agents in depression treatment 
regimens alleviates depressive symptoms. Future studies need to evaluate the direct effect of 
TNFi treatment on the levels of inflammatory cytokines among RA patients with comorbid 
depression. 
In our study population of depression free adults with RA, 39.8% responded to TNFi 
therapy. The response rate to TNFi in this sub group is slightly higher as compared to response 
rate (DAS-28 based response criteria) to TNFi observed in RA population in previous studies 
using registry and administrative claims data. These differences in the analysis could be 
attributed to differences in databases as well as the sub-population used. Our study excluded 
patients with depression. It has been documented that adults with depression have lower rates of 
response to TNFi therapy as compared to those without depression 142.  One study using a Danish 
registry data reported a response rate of 25% to TNFi 143. Curtis et al. using Veterans Health 
Administration database reported a response rate of 27% to TNFi therapy based on algorithm 
defined treatment response109. Other studies using the same algorithm on different databases 
such as Medco Health Solutions Pharmacy Benefit Manager Database144 and Texas Medicaid 
database145 reported 32% and 15.7% response rate respectively with TNFi therapy in RA 
patients.  
Our study findings showed that the major reason for non-response to TNFi therapy was 
low adherence, with about 42% of the RA patients having low adherence to TNFi. This finding is 
consistent with previous studies on RA patients that also highlighted non-adherence to TNFi as 
one of the major contributing factor for poor response to TNFi therapy109,144-146. For example, in 
a prospective multicenter large cohort study conducted in UK, researchers demonstrated that 
self-reported non-adherence to TNFi was a strong predictor of poor response to TNFi therapy, 
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independent of socio demographic and clinical characteristics of the patients146. Therefore, 
physicians should encourage patients to adhere to RA treatment regimens and make them aware 
that low adherence to TNFi medications adversely affect treatment response.   
This study has many strengths. First it adds to the nascent literature on how treatment 
response to antirheumatic therapy may have potential benefit in reducing psychiatric 
comorbidities such as depression in RA patients. Other strengths include the use of the nationally 
representative data of commercially insured working age adults (18 to 63 years), use of 
longitudinal study design to track individuals across different providers, settings over a period of 
3 years, availability of prescription drug claims, ability to measure treatment response with 
readily available claims data, large sample size, high validity and complete information of 
prescription drugs and the use of statistical techniques to control for unobserved selection bias.  
The findings of this study should be interpreted considering the potential limitations that 
include the lack of severity measures for chronic conditions and lack of information on 
individual characteristics such as race, body mass index, exercise and smoking status that may 
predict depression. Furthermore, the study findings are not generalizable beyond commercially 
insured working age adults. Also because of the nature of claims data we can only observe 
prescription of medications and not actual use of medications. Other limitations include selection 
bias due to unobserved variables and underdiagnoses of depression in claims data. 
4.6 Conclusion 
In summary, RA patients who responded to TNFi were less likely to develop depression 
as compared to RA patients who did not respond to TNFi therapy. This finding highlights the 
need of optimal treatment response to TNFi for attenuating the heightened risk of depression 
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associated with RA. Prospective clinical and population based registry studies are needed to 
investigate the role of inflammation in the pathogenesis of depression in patients with RA.  
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Table 4.1. Components of the Algorithm for TNFi Response Status at 1 year after TNFi Initiation (N=4,222) 
Low adherence to index TNFi (PDC<0.8) 42.9% 
Switched to new biologics 18.8% 
Dose escalation of TNFi 9.2% 
Conventional DMARD addition after index 2.6% 
Dose increase of oral glucocorticoid 24.4% 
> 1 glucocorticoid joint injection 6.1% 
TNFi Responders 39.8% 
TNFi Non-responders 60.2% 
 
Note: Based on 4,222 working age adults with RA, initiated on Tumor Necrosis Factor Inhibitors between 
2010 and 2013, aged between 18 and 62, with continuous enrollment for 3 years in a commercial 
insurance plan. Individual components of TNFi response criteria will not add to 39.8% because an 
individual may satisfy one component of the algorithm, while failing to satisfy another component of the 
algorithm.  
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Table 4.2. Selected Baseline Characteristics of TNFi Responders vs. TNFi Non-Responders 
  
Prior to IPTW After applying IPTW 
  
Responder Non-Responder 
 
Responder Non-Responder 
 
    Col% Col% Sig Weighted Col% Weighted Col% Sig 
Sex   0.04   0.87 
 Female 74.6 76.8  74.0 74.2  
 Male 25.4 23.2  26.0 25.8  
Age   < .001   0.98 
 18-34 years 7.4 9.6  8.6 8.6  
 35-44 years 15.1 17.5  16.6 16.5  
 45-54 years 36.0 35.8  35.8 35.9  
 55-62 years 41.4 37.1  39.0 39.0  
Region   0.002   0.65 
 East 18.0 17.0  17.2 17.3  
 Midwest 31.9 28.6  29.9 29.8  
 South 41.2 46.0  44.7 44.7  
 West 8.9 8.4  8.2 8.2  
Insurance Plan Type  < .001   0.98 
 HMO 9.7 10  10.0 10.0  
 PPO 76.0 78.8  77.9 77.9  
 Other 14.3 11.2  12.1 12.1  
NSAIDS   0.420   0.98 
 Yes 56.3 55.3  55.4 55.3  
 No 43.7 44.7  44.6 44.7  
Methotrexate   < .001   0.68 
 Yes 76.4 70.7  72.6 72.5  
 No 23.6 29.3  27.5 27.5  
Other DMARDS†  0.240   0.95 
 Yes 51.0 49.5  49.2 49.2  
 No 49.0 50.5  50.8 50.8  
Glucocorticoids   < .001   0.99 
 Yes 67.4 75.0  71.8 71.7  
 No 32.6 25.0  28.2 28.3  
Narcotics   < .001   0.99 
 Yes 51.9 58.8  54.1 54.0  
 No 48.1 41.2  45.9 46.0  
 
Note: Based on 4,222 working age adults with RA, initiated on Tumor Necrosis Factor Inhibitors between 2010 and 
2013, aged between 18 and 62, with continuous enrollment for 3 years in a commercial insurance plan. † Other 
DMARDS include Sulfasalazine, Leflunomide, Hydroxychloroquine, Azathioprine, Chloroquine, 
Cyclophosphamide, Cyclosporine, Minocycline, and Sodium Aurothiomalate.  
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Table 4.3. Adjusted Odds Ratio and 95% Confidence Intervals of Selected Significant Variables  
from Logistic Regression on Newly Diagnosed Depression  
among Working Age Adults with RA initiated on TNFi  
QuintilesIMS Real-World Data Adjudicated Claims Database   
Newly Diagnosed Depression 
     AOR  95% CI Sig 
TNFi Response    
 Yes 0.80 [0.64,0.98] * 
 No    
Sex    
 Female    
 Male 0.53 [0.40,0.70] *** 
ED Visit    
 Yes 1.32 [1.04,1.68] * 
 No    
Opioid Use    
 Yes 2.07 [1.69,2.52] *** 
 No    
Number of Clinical Conditions   
 0    
 1 to 3 1.15 [0.90,1.46]  
 > 3 1.97 [1.34,2.88] *** 
 
Note: Based on 4,222 working age adults with RA, initiated on Tumor Necrosis Factor Inhibitors between 2010 and 
2013, aged between 18 and 62, with continuous enrollment for 3 years in a commercial insurance plan. AOR= 
Adjusted Odds Ratio, CI= Confidence Interval. *** p < .001; ** .001 ≤ p < .01; * .01 ≤ p < .05. Other factors that 
were adjusted in the model included age, region, insurance plan type, index year, inpatient visit, anxiety, substance 
abuse, glucocorticoid use, methotrexate use, other disease modifying antirheumatic drugs use, non-steroidal anti-
inflammatory drug use and narcotic use. 
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CHAPTER 5 
5 Summary and Conclusion 
5.1 Summary 
Understanding depression as a comorbidity in medical conditions is very important 
because depression has been identified as the second leading cause of disability that imposes the 
highest burden on working-age population 147.  The World Health Survey reported that 
depression leads to the greatest decrement in health compared to any chronic physical conditions 
such as angina, asthma, arthritis and diabetes as reported by the World Health Organization 148. 
Again, data from the National Comorbidity Survey Replication, a nationally representative 
household survey in the U.S. have shown that the overall burden of functional disability is 
significantly higher with depression than with chronic medical disorders 149. The burden of 
depression is significant because almost 80% of individuals with depression have some level of 
functional impairment due to depression150.  
The link between RA and depression is very complex and influenced by a multitude of 
factors such as shared pathophysiologic pathways of inflammation, RA-related treatment 
response, as well as the patient’s demographic and socio-economic factors, and general 
difficulties in coping with the disease. Depression can increase the clinical, humanistic, and 
economic burden among RA patients. Growing evidence now suggest that depression is a 
systemic inflammatory condition and may exert negative influence on the treatment response in 
RA by its effect on pro-inflammatory cytokines. Therefore, it is important to understand how 
depression is related to the treatment effectiveness of specific cytokine inhibitor drugs such as 
Tumor Necrosis Factor Inhibitor (TNFi) therapy that are used for the treatment of RA.  The 
powerful anti-inflammatory effect of TNFi may have a potential beneficial effect in reducing the 
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risk of depression in RA patients. In real-world clinical practice only one-third of RA patients 
respond to TNFi therapy (Curtis, Schabert et al. 2014). Therefore, it is important to assess the 
relationship between treatment response to TNFi and the risk of developing depression.  
However, a comprehensive examination of how depression affects RA and how RA can 
affect depression in real-world clinical practice settings is lacking. As the onset of both RA and 
depression occurs during the prime working years of lives, it is important to analyze these issues 
in working-age adults with RA. Therefore, this dissertation had three related aims focusing on 
working-age adults: 1) estimating the illness burden of depression in RA; 2) how depression can 
affect RA treatment response; and 3) how RA treatment response can affect depression.   The 
study used data from multiple nationally representative sources to triangulate the complex 
relationship between RA and depression in working-age adults. These data sources were: the 
nationally representative Medical Expenditure Panel Survey (MEPS) for years 2009, 2011, 2013, 
and 2015 and a retrospective claims database for commercially insured working-age adults for 
the years 2009 through 2015.   
Illness Burden of Depression in RA 
We found that one in every four working-age adults reported prevalent depression. 
Presence of depression in RA patients was associated with excess clinical, humanistic and 
economic burden. For example, depression was associated with severe pain related interference 
with normal work, lower HRQoL scores in the mental health domain, higher annual healthcare 
expenditures and out-of-spending burden. Compared to RA patients without depression, adults 
with RA and depression were significantly more likely to be unemployed and among employed 
adults those with depression had a significantly higher number of missed work days and higher 
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lost wages due to missed work days. These findings underscore the magnitude of clinical, 
humanistic and economic burden associated with depression among working-age adults with RA. 
The interaction between Depression and RA treatment response  
Depression was independently associated with treatment response to TNFi, even after 
adjusting for baseline predisposing, enabling, need and external environment factors among 
working-age RA patients. Among RA patients with depression, nearly three in every ten patients 
responded to TNFi therapy, whereas among RA patients without depression, nearly four in every 
ten patients responded to TNFi therapy. Post-regression non-linear decomposition analysis 
revealed that differences in baseline characteristics such as the presence of anxiety, 
glucocorticoid use and narcotic pain medication use, explained a substantial portion of the 
observed difference in treatment response to TNFi between RA patients with depression and 
without depression.  
In addition, among RA patients without baseline depression, those who responded to 
TNFi therapy, were less likely to develop depression as compared to those who did not respond 
to TNFi therapy. Among RA patients who responded to TNFi therapy, seven out of every 
hundred patients developed depression, whereas, among RA patients who did not respond to 
TNFi therapy, nine out of every hundred patients developed depression. This finding suggests 
that effective treatment with TNFi reduces the risk of depression among RA patients. 
5.2 Implications  
This dissertation research revealed that depression was associated with excess burden in 
many dimensions: pain-related work interference, health related quality of life, lost productivity, 
and healthcare costs among working-age adults with RA. The study findings have important 
implications for the employers because depression costs U.S. employers more than $31 billion 
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annually due to missed work and decreased work performance 96. One study done in the U.S. 
reported that depression leads to the highest reduction in work performance and the highest 
employer burden relative to any other chronic conditions 97.Strategies that employers may adopt 
to improve mental health in employees include organizing workplace health promotion programs 
and stress management projects, which have shown the benefits of prevention and management 
of depression in workplace98,99. 
Our study findings have implications for clinicians and healthcare providers.  It is well-
documented that depression in RA patients is often under recognized and under-treated in routine 
clinical practice (Hider, Tanveer et al. 2009, Margaretten, Julian et al. 2011). The current study 
also highlighted the negative effect of depression on treatment response to TNFi therapy.  Our 
study underscores the need of incorporating depression screening and suggest the need 
developing effective clinical interventions for co-managing depression and RA in routine clinical 
practice. Potential strategies can include the integration of mental health services with 
rheumatology practice and facilitating mental health training for rheumatologists. 
The reduction in the risk of depression in TNFi responders suggests that TNFi therapy is 
important not only for clinical improvement in RA disease but also for reducing the risk of 
depression. Therefore, aggressive and early treatment of RA with TNFi therapy may be needed 
to reduce the risk of developing depression, which may further improve treatment response. 
Thus, promoting the use of RA medications that has additional benefit in reducing the risk of 
depression in RA patients will help in reducing the excess burden of depression.  Reducing the 
risk of depression may reduce overtreatment of RA with RA medications because depression is 
associated with poor treatment response and clinicians need to adjust RA treatment for those who 
are responding poorly to medications. Our study findings offer the possibility of including anti-
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inflammatory agents in treating existing depression and testing whether including anti-
inflammatory agents in depression treatment regimens alleviates depressive symptoms. Future 
studies need to evaluate the direct effect of TNFi treatment on the levels of inflammatory 
cytokines among RA patients with comorbid depression. 
Future studies need to assess whether treatment of depression with antidepressants in 
collaborative care settings improve treatment response and RA-related clinical outcomes 
associated with particular anti-rheumatic therapies.  Appropriate management of depression in 
RA would not only improve depression but also improve RA outcomes.   
Our findings can inform payers and other stake-holders.  Our study findings have 
important implications for the emerging trend that focus on “value-based” care, which emphasize 
on quality care at lower costs.  These programs now require physicians to consider alternative 
payment models such as accountable care organizations, medical homes, bundled payments that 
emphasize quality and resource use. In all these programs, the payers and providers need to 
consider the case-mix of patients to benchmark expenditures and show value. Under bundled 
payment systems, a certain amount of prospective payment is made for episodes of care provided 
for a condition (example:  depressive episodes in RA patients).  Our estimate of excess direct 
medical expenditures associated with depression suggest that providers need to consider 
depression for risk adjustment, benchmarking expenditures, and in setting payments for episodes 
of care.  
5.3 Unique Contributions of this Study 
This study filled a critical knowledge gap.  To the best of our knowledge, this is the first 
population based study that comprehensively examined the excess clinical, humanistic and 
economic burden of depression in working-age adults with RA.  One of the unique contributions 
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of this study is that it provided a nation-wide estimation of direct medical costs and productivity 
losses associated depression in working-age adults with RA.  
By analyzing how treatment response to anti-rheumatic therapy may have the potential 
benefit in reducing psychiatric comorbidities such as depression in RA patients, our study 
findings add to the nascent literature on co-management of chronic physical and mental health 
conditions.  
To understand the association between depression and treatment response, this study 
employed an econometric technique (i.e. decomposition).  The decomposition technique 
quantified the contribution of individual patient characteristics in explaining the observed 
difference in treatment response to TNFi between RA patients with and without depression. 
This study focused on patient experiences in with real world clinical settings. By 
examining the effect of mental health conditions (i.e. depression) in RA, this study highlights the 
complex relationship between mental health conditions and physical conditions. This study was 
more in line with real world experiences of the patients because the effectiveness of depression 
treatments were examined among individuals with multiple coexisting chronic physical 
conditions, a population often not included in clinical trials 151. 
5.4 Strengths and Limitations 
The strengths of this study include the use of nationally representative datasets, use of 
longitudinal study design to track individuals across different providers, settings over a period of 
3 years, availability of prescription drug claims, ability to measure the treatment response with 
readily available claims data, large sample size, the use of robust statistical techniques such as 
GLM, and recycled prediction in estimating the incremental costs and missed workdays, high 
validity and complete information of prescription drugs. 
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Some of the potential limitations of our study include lack of severity measures RA and 
depression.  However, by restricting adults who initiated TNFi therapy, we only included adults 
with moderate to severe RA.  We did not have information on physiologic characteristics and 
lifestyle risk factors that may affect treatment response. Furthermore, the study findings of aim 2 
and aim 3 are not generalizable beyond commercially insured working age adults. Also, because 
of the nature of claims data, we can only observe prescription fills and not actual use of 
medications. Other limitations include selection bias due to observable and unobserved variables 
and underdiagnoses of depression in claims data. 
5.5 Conclusion 
Depression is associated with excess illness burden in working-age adults with RA. RA 
treatment effectiveness is affected by depression and effective RA treatment reduced the risk of 
developing depression. Although this study filled a critical knowledge gap, future research needs 
to confirm our study findings by including RA disease activity, inpatient preferences, and 
personal health practices that may affect the relationship between treatment effectiveness and 
depression. Future studies need to evaluate whether treatment with the TNFi has direct effect on 
the levels of inflammatory biomarkers such as c-reactive protein (CRP), interleukins and tumor 
necrosis factors in patients with RA and depression. 
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7 Appendices 
Appendix 7.1. Chapter 2. Description of Study Sample   
Working-Age (18 to 64 years) Adults with Rheumatoid Arthritis  
Medical Expenditure Panel Survey (2009, 2011, 2013 and 2015) 
    N Weighted N Weighted% 
All     2,662               5,719,998  100.0 
Gender    
 Female     1,826               3,661,958  64.0 
 Male        836               2,058,040  36.0 
Race/Ethnicity    
 White     1,061               3,596,249  62.9 
 African American        778                  989,822  17.3 
 Latino        639                  780,416  13.6 
 Other        184                  353,511  6.2 
Age in years    
 18-39 years        444                  956,652  16.7 
 40-49 years        609               1,271,670  22.2 
 50-59 years     1,080               2,326,292  40.7 
 60-64 years        529               1,165,384  20.4 
Marital Status    
 Married     1,287               3,098,420  54.2 
 Widow/Separated/Divorced        845               1,630,180  28.5 
 Never married        530                  991,398  17.3 
Education    
 Less than High School        665               1,007,827  17.6 
 High School        939               2,043,963  35.7 
 More than High School     1,036               2,623,400  45.9 
Poverty Status    
 Poor        740               1,216,767  21.3 
 Not Poor        675               1,204,168  21.1 
 Middle Income        708               1,670,010  29.2 
 High Income        539               1,629,054  28.5 
Insurance Status    
 Private     1,302               3,411,533  59.6 
 Public        932               1,580,322  27.6 
 Uninsured        428                  728,144  12.7 
Employment    
 Employed     1,309               3,071,100  53.7 
 Not Employed     1,352               2,647,283  46.3 
Region    
 Northeast        383                  984,779  17.2 
 Mid-west        523               1,264,228  22.1 
 South     1,190               2,454,395  42.9 
 West        566               1,016,597  17.8 
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Appendix 7.1. Chapter 2. Description of Study Sample   
Working-Age (18 to 64 years) Adults with Rheumatoid Arthritis  
Medical Expenditure Panel Survey (2009, 2011, 2013 and 2015) 
    N Weighted N Weighted% 
All     2,662               5,719,998  100.0 
Perceived Physical Health     
 Excellent/very good        607               1,488,614  26.0 
 Good        871               2,001,187  35.0 
 Fair/poor     1,184               2,230,197  39.0 
Perceived Mental Health      
 Excellent/very good 607 1,488,614 26.0 
 Good 871 2,001,187 35.0 
 Fair/poor 1184 2,230,197 39.0 
Multimorbidity    
 RA only        716               1,605,886  28.1 
  Multimorbidity     1,946               4,114,112  71.9 
Anxiety 
   
 Yes        494               1,134,341  19.8 
 No     2,168               4,585,657  80.2 
Obesity    
 Obese     1,218               2,521,340  44.1 
 Not Obese     1,392               3,084,702  53.9 
Smoking Status    
 Current smoker        698               1,567,457  27.4 
 Other     1,755               3,729,925  65.2 
 Missing        209                  422,616  7.4 
Exercise 
   
 Yes     1,077               2,364,802  41.3 
 No      1,568               3,321,567  58.1 
     
 
Note: Based on 2,662 adults with Rheumatoid Arthritis, aged between 18 and 64 years, who were alive during the 
calendar year.    Missing data for the following variables (education, obesity, smoking, and exercise) are not 
presented.  
 
Weighted N and percentages were derived by dividing the person weights by the number of years pooled. 
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Appendix 7.2.  Chapter 3. Baseline Characteristics of Working-Age (18 to 62 years)  
RA Patients Initiated on TNFi therapy from 
QuintilesIMS RWD Adjudicated Claims Database  
     N   %  
Total                   4,222  
 
Sex    
 Female                    3,216  76.2 
 Male                    1,006  23.8 
Age    
 18-34 years                       352  8.3 
 35-44 years                       732  17.3 
 45-54 years                    1,534  36.3 
 55-62 years                    1,604  38.0 
Region   
 East                       712  16.9 
 Midwest                    1,253  29.7 
 South                    1,917  45.4 
 West                       340  8.1 
Insurance Plan Type   
 HMO                       399  9.5 
 PPO                    3,324  78.7 
 Other                       499  11.8 
Index Year   
 2010                       519  12.3 
 2011                    1,364  32.3 
 2012                    1,276  30.2 
 2013                    1,063  25.2 
Number of Chronic Conditions  
 0                    1,306  30.9 
 1 to 3                    2,487  59 
 > 3                       429  10 
Anxiety   
 Yes                       255  6.0 
 No                    3,967  94.0 
Substance Abuse   
 Yes                         50  1.2 
 No                    4,172  98.8 
ER Visit   
 Yes                       944  22.4 
 No                    3,278  77.6 
IP Visit   
 Yes                       348  8.2 
 No                    3,874  91.8 
NSAIDS   
 Yes                    2,325  55.1 
 No                    1,897  44.9 
Methotrexate   
 Yes                    3,104  73.5 
 No                    1,118  26.5 
Other DMARDS†   
 Yes                    2,079  49.2 
 No                    2,143  50.8 
Glucocorticoids   
 Yes                    3,001  71.1 
 No                    1,221  28.9 
(Continued)   
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Note: Based on 4,222 working age adults with RA, initiated on Tumor Necrosis Factor Inhibitors between 2010 
and 2013, aged between 18 and 62, with continuous enrollment for 3 years in a commercial insurance plan. † 
Other DMARDS include Sulfasalazine, Leflunomide, Hydroxychloroquine, Azathioprine, Chloroquine, 
Cyclophosphamide, Cyclosporine, Minocycline, and Sodium Aurothiomalate 
  
Narcotics 
 Yes                    2,315  54.8 
  No                    1,907  45.2 
 
 
104 
 
Supplemental Figure 7.1.1. Chapter 3. Flow Diagram of Study Cohort  
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Supplemental Figure 7.1.1. Chapter 4. Flow Diagram of Study Cohort 
 
 
